Organigram (NASDAQ: OGI) buys Sanity Group and lifts 2026 outlook amid hemp risks

Rhea-AI Filing Summary

Organigram Global Inc. reported Q2 Fiscal 2026 net revenue of $59,794, down 9% from Q2 Fiscal 2025 as recreational cannabis sales fell. Gross margin before fair value adjustments declined to 25% and adjusted EBITDA dropped to $870, reflecting weaker product mix and higher returns provisions. The quarter swung to a net loss of $921 versus prior-year net income of $42,456, driven mainly by smaller fair value gains on derivatives and a $5,800 impairment on its U.S. hemp-derived products business.

For the six months ended March 31, 2026, net revenue rose 14% to $123,332, with adjusted gross margin improving to 34% and net income at $19,048. Organigram closed the acquisition of German operator Sanity Group in April 2026 for upfront consideration of €107.3 million and updated Fiscal 2026 guidance, now projecting net revenue to exceed $350 million, with adjusted EBITDA and adjusted gross margin expected to surpass Fiscal 2025 levels and free cash flow around break even. The company highlights strong international expansion, including Germany and Australia, but faces regulatory headwinds for U.S. hemp-derived THC products and continues to remediate a material weakness in internal controls over financial reporting.

Positive

• Raised Fiscal 2026 outlook with larger revenue base: Net revenue guidance increased from exceeding $300 million to exceeding $350 million, with management also expecting adjusted gross margin and adjusted EBITDA to surpass Fiscal 2025 and free cash flow to be approximately break even.
• Strategic international expansion via Sanity Group acquisition: Closed the purchase of Sanity Group for upfront consideration of €107.3 million and reaffirmed expectations that Sanity Group revenue will average about €25 million per quarter, strengthening exposure to Germany’s medical cannabis market and broader European growth.

Negative

• Profitability pressure and Q2 loss driven by margin mix: Q2 Fiscal 2026 net revenue declined 9% to $59,794, adjusted EBITDA fell to $870, and the quarter posted a net loss of $921 as gross margin before fair value adjustments dropped to 25% amid lower recreational sales and higher returns provisions.
• Regulatory and accounting control risks: A $5,800 impairment was recognized for a cash‑generating unit exposed to new U.S. hemp‑derived product restrictions, and management acknowledges an ongoing material weakness in internal control over financial reporting related to complex biological asset and inventory valuation spreadsheets.

Insights

Cannabis sector & financial reporting analyst

Q2 margins softened, but 2026 guidance and Sanity Group deal support a neutral overall view.

Organigram delivered six‑month net revenue of $123,332 (up 14% year over year), yet Q2 standalone results weakened. Net revenue fell to $59,794 and adjusted EBITDA slid to $870, as recreational sales declined and product mix shifted away from higher‑margin categories.

The April 2026 acquisition of Sanity Group for €107.3 million, backed by a €40.3 million BAT private placement and up to $60 million in new credit facilities, underpins a more international, medical‑focused growth profile. Management raised Fiscal 2026 net revenue guidance from above $300 million to above $350 million, while still targeting higher adjusted gross margin and adjusted EBITDA than Fiscal 2025 and approximately break‑even free cash flow.

Risks remain material. The company recorded a $5,800 impairment tied to U.S. hemp‑derived products and expects to sell, wind down or restructure those activities if U.S. federal law is not changed by November 2026. It also continues to remediate a material weakness in internal control over financial reporting related to complex spreadsheets for biological assets and inventory. Future filings discussing progress on control remediation and the performance of Sanity Group will be important for assessing execution against the updated 2026 outlook.

Key Figures

Q2 2026 net revenue: $59,794 Q2 2026 adjusted EBITDA: $870 Six-month net revenue: $123,332 +5 more

8 metrics

Q2 2026 net revenue $59,794 Three months ended March 31, 2026

Q2 2026 adjusted EBITDA $870 Three months ended March 31, 2026

Six-month net revenue $123,332 Six months ended March 31, 2026

Six-month net income $19,048 Six months ended March 31, 2026

Impairment of intangible assets $5,800 Q2 Fiscal 2026 impairment on U.S. hemp-derived products CGU

Sanity Group purchase price €107.3 million Upfront consideration at April 2026 closing

Revised 2026 revenue guidance > $350 million Fiscal 2026 net revenue projection

Cash and short-term investments $54,754 Balance as of March 31, 2026

Key Terms

Adjusted EBITDA, gross margin before fair value adjustments, cash-generating units, EU-GMP certification, +2 more

6 terms

Adjusted EBITDA financial

"Adjusted EBITDA4 was $870 in Q2 Fiscal 2026, compared to $4,908 in Q2 Fiscal 2025."

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

gross margin before fair value adjustments financial

"The Company realized gross margin before fair value adjustments for Q2 Fiscal 2026 of $14,994, or 25% as a percentage of net revenue."

cash-generating units financial

"the Company identified impairment indicators for one of its two cash-generating units ("CGUs"), primarily due to new regulatory restrictions affecting hemp-derived products in the U.S."

EU-GMP certification regulatory

"Growth is expected to be supported, in part, by the anticipated EU-GMP certification of the Company’s Moncton facility."

EU-GMP certification is an official approval that a drug or medical product maker follows the European Union’s Good Manufacturing Practice standards for consistent, safe production. For investors it signals lower regulatory and quality risk, smoother access to EU markets, and greater likelihood that products will pass inspections—similar to a restaurant earning a high food-safety grade showing reliable, repeatable processes.

material weakness in ICFR regulatory

"management identified a material weakness in ICFR, and the Company’s independent registered public accounting firm issued an adverse opinion on the effectiveness of the Company’s ICFR"

fair value of biological assets financial

"Unrealized gain on changes in fair value of biological assets for the six months ended March 31, 2026 was $39,956"

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-38885

ORGANIGRAM GLOBAL INC.

(Translation of registrant’s name into English)

145 King Street West, Suite 1400

Toronto, Ontario ,Canada M5H 1J8

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ ]           Form 40-F [ X ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]

SUBMITTED HEREWITH

Exhibits

99.1			Management's Discussion and Analysis for the three and six months ended March 31, 2026
99.2			Condensed Consolidated Interim Unaudited Financial Statements for the three and six months ended March 31, 2026
99.3			Form 52-109F2 - Certification of Interim Filings of Chief Executive Officer dated May 12, 2026
99.4			Form 52-109F2 - Certification of Interim Filings of Chief Financial Officer dated May 12, 2026
99.5			News Release announcing results for the three and six months ended March 31, 2026 dated May 12, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ORGANIGRAM GLOBAL INC.

/s/ Greg Guyatt

Greg Guyatt

Chief Financial Officer

Date: May 12, 2026

INTRODUCTION

This Management’s Discussion and Analysis dated May 12, 2026 (this "MD&A") should be read in conjunction with the unaudited condensed consolidated interim financial statements (the “Interim Financial Statements”) of Organigram Global Inc. (together with its subsidiaries, the “Company”, "Organigram", "we", "us", or "our") for the three and six months ended March 31, 2026 (“Q2 Fiscal 2026”) and March 31, 2025 ("Q2 Fiscal 2025"), and the audited annual consolidated financial statements for the year ended September 30, 2025 ("Fiscal 2025") (the "Annual Financial Statements" and together with the Interim Financial Statements, the "Financial Statements"), including the accompanying notes thereto.

Financial data in this MD&A is based on the Financial Statements of the Company, and has been prepared in accordance with International Financial Reporting Standards ("IFRS Accounting Standards" or "IFRS") as issued by the International Accounting Standards Board (“IASB”), unless otherwise stated. All financial information in this MD&A is expressed in thousands of Canadian dollars (“$”), except for share and per share calculations, references to $ millions and $ billions, per gram (“g”) or kilogram (“kg”) of dried flower and per milliliter (“mL”) or liter (“L”) of cannabis extracts calculations.

Refer to the cautionary statements regarding forward-looking information and non-IFRS measures found at the end of this MD&A.

BUSINESS OVERVIEW

NATURE OF THE COMPANY’S BUSINESS

Organigram is a licensed cannabis cultivator and producer of consumer packaged goods containing cannabis. The Company manufactures and distributes cannabis products to wholesale and retail channels in Canada, exports to international jurisdictions, and distributes hemp-derived tetrahydrocannabinol ("THC") beverages and edibles in the U.S. (See amendments to the definition of hemp in the 2018 Farm Bill as described in greater detail in the "Outlook" section of this MD&A). Subsequent to Q2 Fiscal 2026, Organigram acquired Sanity Group GmbH ("Sanity Group"), a German cannabis leader with expanding operations in Poland, Czechia, the United Kingdom (UK), and Switzerland.

Organigram operates five facilities across Canada:

Moncton Campus (Indoor Cultivation and Manufacturing)

The Moncton Campus is home to our 500,000+ square foot state-of-the-art flagship facility, which features three-tiered, strain-specific grow rooms with the ability to control critical environmental factors specific to the needs of each strain. The facility's capabilities include extraction, cannabinoid testing, and automated production and packaging lines. We have invested in cost-effective seed-based production, which contributes to efficiency through faster room turns, lower plant care, and higher yields. We are further enhancing these benefits through a proprietary genetic discovery that enables early identification of powdery mildew resistance in seedlings, contributing to the reduction of crop loss and production costs over time. Previously, confirming mildew resistance required approximately 90 days. With this discovery, screening can now occur within 10 days, enabling early removal of out-of-spec populations and reducing downstream crop loss and waste. This screening tool is proprietary and applicable across a wide range of genetics, unlike existing markers that are limited in scope.

Winnipeg Facility (Ingestible Products Manufacturing)

The Winnipeg Facility is a purpose-built, highly automated 51,000 square-foot ingestibles manufacturing facility. The facility also contains specialized manufacturing equipment for the Company's FASTTM (Fast Acting Soluble Technology) nanoemulsion technology ("FASTTM") used in some of its ingestible products.

Lac-Supérieur Facility (Hash/Concentrates and Premium Flower)

The Lac-Supérieur Facility is a greenhouse facility which provides a strategic footprint in Quebec, spans 33,000 square feet of space.

Aylmer Facility (Extraction and Manufacturing)

The Aylmer Facility houses advanced extraction and manufacturing capabilities, including hydrocarbon and CO2 extraction refinement, formulation, post-processing of minor cannabinoids, and infused and regular pre-roll production.

London Facility (Warehousing and Distribution)

The London Facility is a centralized warehouse distribution hub in Ontario. The facility supports growing demand for Organigram's products, optimizes fulfillment, and reduces the cost and complexity of shipping products from the Moncton Campus to Central and Western Canada.

As of the end of Q2 Fiscal 2026, Organigram held the #1 market share position in the Canadian recreational cannabis market1.

1 Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of March, 2026.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    1

STRATEGY

Our corporate strategy is to leverage our strengths in innovation, consumer focus, efficiency, and market expansion to profitably drive global growth and shareholder value.

1. Innovation

We are committed to maintaining a culture of innovation and have a track record of launching differentiated products that quickly capture market share.

Organigram maintains a Product Development Collaboration (“PDC”) with a wholly-owned subsidiary of British American Tobacco p.l.c. ("BAT"), its largest institutional shareholder and a leading multi-category consumer goods company, to develop next-generation cannabis products. Through the PDC we established a Centre of Excellence (“CoE”) at the Moncton Campus where we are licensed to conduct research on cannabis. Under the PDC agreement dated March 10, 2021, Organigram is granted a worldwide, royalty‑free, non‑transferable license to any intellectual property developed by the PDC—sole in Canada and non‑exclusive internationally—on a perpetual basis. Both companies contribute scientists, researchers, and product developers to the CoE, which is jointly governed by a steering committee composed of equal representation from Organigram and BAT.

2. Consumer Focus

We maintain a diversified brand and product portfolio with competitive pricing that is aligned with evolving consumer preferences which we monitor through consumer and market research and social engagement.

3. Efficiency

We continue to reduce costs and improve scalability and margins through ongoing investments in facility automation, cultivation practices (including seed-based cultivation), and logistics efficiency, particularly at our London Facility.

4. Market Expansion

Organigram is committed to expanding its market presence through both organic growth and strategic diversification. Our key initiatives have included:

•Domestic expansion: acquisitions of cannabis cultivation and production facilities across Ontario, Québec, and Manitoba, enabling participation in all major Canadian product categories.

•International flower exports: shipments of bulk cannabis to Germany, Australia, and the UK, strengthening Organigram’s position as a reliable global supplier. Our recent acquisition Sanity Group in April, 2026, positions us for international revenue growth primarily from Germany's medical cannabis market, with additional growth initiatives ongoing in Switzerland, the UK, Poland, and Czechia.

•Strategic investment from BAT: Between 2021 and 2026, BAT made three strategic investments in Organigram for total gross proceeds of approximately $410 million. The proceeds have been used to establish the PDC, support R&D related to next-generation cannabis products, fund Organigram’s international strategic investments, including the acquisition of Sanity Group, and for general corporate purposes.

•International branded products: Expansion into the U.S. hemp-derived THC beverage and edibles market through the acquisition of Collective Project Limited (“CPL”) and the launch of happly, a lifestyle edibles brand focused on consumer mood states and functional ingredients2. In Q2 Fiscal 2026, Organigram also launched 10 vape and edibles SKUs in the Australian medical market, with products expected to be available through a network of over 4,000 pharmacies.

2 See amendments to definition of hemp in the 2018 Farm Bill as described in greater detail in the "Outlook" section of this MD&A.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    2

KEY QUARTERLY FINANCIAL AND OPERATING RESULTS

			Q2-2026						Q2-2025						CHANGE						% CHANGE
Financial Results
Net revenue			$	59,794					$	65,600					$	(5,806)					(9)		%
Cost of sales			$	44,800					$	45,813					$	(1,013)					(2)		%
Gross margin before fair value adjustments			$	14,994					$	19,787					$	(4,793)					(24)		%
Gross margin % before fair value adjustments(1)			25 %						30 %												(5)		%
Operating expenses			$	32,000					$	26,001					$	5,999					23		%
Other income			$	(14,672)					$	(49,933)					$	(35,261)					(71)		%
Adjusted EBITDA(2)			$	870					$	4,908					$	(4,038)					(82)		%
Net (loss) income			$	(921)					$	42,456					$	(43,377)					nm
Net cash used in operating activities			$	(6,760)					$	(16,585)					$	(9,825)					(59)		%
Adjusted Gross Margin(2)			$	18,441					$	21,921					$	(3,480)					(16)		%
Adjusted Gross Margin %(2)			31 %						33 %												(2)		%

Note (1):    Equals gross margin before fair value adjustments (as reflected in the Interim Financial Statements) divided by net revenue.

Note (2):    Adjusted EBITDA, adjusted gross margin and adjusted gross margin % are non-IFRS Measures. See "Cautionary Statement Regarding Certain Non-IFRS Measures" and "Financial Results and Review of Operations" in this MD&A.

REVENUE

For Q2 Fiscal 2026, the Company reported $59,794 in net revenue. Of this amount, $50,045 (84%) was attributable to recreational cannabis sales, $6,090 (10%) to international sales, and $3,659 (6%) to other revenues. Q2 Fiscal 2026 net revenue decreased 9%, or $5,806, from Q2 Fiscal 2025 net revenue of $65,600, primarily due to a decrease of $6,614 in recreational cannabis sales.

COST OF SALES

Cost of sales for Q2 Fiscal 2026 decreased to $44,800 compared to $45,813 in Q2 Fiscal 2025, primarily due to a decrease in net revenue of 9% in Q2 Fiscal 2026 compared to Q2 Fiscal 2025. Included in Q2 Fiscal 2026 cost of sales are $3,447 of inventory provisions for unsalable inventories. Q2 Fiscal 2025 had inventory provision adjustments of $548.

GROSS MARGIN BEFORE FAIR VALUE ADJUSTMENTS AND ADJUSTED GROSS MARGIN

The Company realized gross margin before fair value adjustments for Q2 Fiscal 2026 of $14,994, or 25% as a percentage of net revenue, compared to $19,787, or 30%, in Q2 Fiscal 2025. Adjusted gross margin3 for Q2 Fiscal 2026 was $18,441, or 31% as a percentage of net revenue, compared to $21,921, or 33%, in Q2 Fiscal 2025. The year-over-year decrease in adjusted gross margin was primarily driven by changes in product mix, including a lower proportion of higher-margin product categories, and higher returns provisions.

3 Adjusted gross margin and adjusted gross margin % are non-IFRS Measures. See "Cautionary Statement Regarding Certain Non-IFRS Measures" in this MD&A and the discussion under the heading "Adjusted Gross Margin" and the reconciliation to IFRS measures in the "Financial Results and Review of Operations" section of this MD&A.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    3

OPERATING EXPENSES

			Q2-2026						Q2-2025						CHANGE						% CHANGE
General and administrative			$	14,935					$	14,967					$	(32)					nm
Sales and marketing			8,674						7,523						1,151						15		%
Research & development			2,025						2,662						(637)						(24)		%
Share-based compensation			566						849						(283)						(33)		%
Impairment of intangible assets			5,800						—						5,800						(100)		%
Total operating expenses			$	32,000					$	26,001					$	5,999					23		%

GENERAL AND ADMINISTRATIVE

General and administrative expenses were $14,935 for Q2 Fiscal 2026, compared to $14,967 for Q2 Fiscal 2025. The decrease was primarily driven by lower ERP implementation expenses, partially offset by higher office and general expenses related to the acquisitions of Motif Labs Limited ("Motif") and CPL, as well as a credit loss related to a wholesale customer insolvency.

SALES AND MARKETING

Sales and marketing expenses of $8,674 increased from $7,523 in Q2 Fiscal 2025. The increase was primarily driven by higher investments in advertising, promotions, and trade marketing initiatives to support new product launches in the current period.

RESEARCH AND DEVELOPMENT

R&D costs of $2,025 decreased from $2,662 in Q2 Fiscal 2025. The decrease was primarily driven by lower investment in foundational research within the PDC, reflecting a shift toward more targeted, strategic product development, as well as headcount reductions resulting from synergies realized through the Motif acquisition.

SHARE-BASED COMPENSATION

Share-based compensation expense of $566 decreased from $849 in Q2 Fiscal 2025, primarily due to the timing of vesting of equity awards. There were no such awards granted in Q2 Fiscal 2026.

IMPAIRMENT OF INTANGIBLE ASSETS

During Q2 Fiscal 2026, the Company identified impairment indicators for one of its two cash-generating units ("CGUs"), primarily due to new regulatory restrictions affecting hemp-derived products in the U.S. These developments reduced expected future revenues, profitability, and cash flows. The Company performed an impairment assessment using a value-in-use model based on a four-year management-approved cash flow forecast. As a result, the recoverable amount of the CGU was determined to be approximately $5,800 below its carrying value, and an impairment charge of $5,800 was recognized during the period.

OTHER (INCOME) / EXPENSES

			Q2-2026						Q2-2025						CHANGE						% CHANGE
Investment income, net of financing costs			(312)						(179)						133						74		%
Acquisition and transaction costs			4,356						974						3,382						347		%
Change in fair value of contingent consideration			(4,810)						(3,899)						(911)						23		%
Share issuance costs allocated to derivative liabilities			—						170						(170)						(100)		%
Change in fair value of derivative liabilities, preferred shares and other financial assets			(14,524)						(47,155)						32,631						69		%
Other non-operating expenses			618						156						462						296		%
Total other (income)/expenses			$	(14,672)					$	(49,933)					$	(35,261)					(71)		%

INVESTMENT INCOME (NET OF FINANCING COSTS)

Investment income (net of financing costs) of $312 increased from $179 in Q2 Fiscal 2025, primarily due to a lower lease financing costs in Q2 Fiscal 2026 compared to Q2 Fiscal 2025.

ACQUISITION AND TRANSACTION COSTS

Acquisition and transaction costs of $4,356 increased from $974 in Q2 Fiscal 2025, primarily driven by higher costs associated with the Company's acquisition of Sanity Group.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    4

CHANGE IN FAIR VALUE OF CONTINGENT CONSIDERATION

Change in fair value of contingent consideration was a gain of $4,810 during Q2 Fiscal 2026 compared to a gain of $3,899 in Q2 Fiscal 2025. The current period loss in Q2 Fiscal 2026 was due to the revaluation of the contingent liability payable to the former owners of CPL.

CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES, PREFERRED SHARES AND OTHER FINANCIAL ASSETS

Change in fair value of derivative liabilities, preferred shares and other financial assets was a gain of $14,524 during Q2 Fiscal 2026 compared to $47,155 in Q2 Fiscal 2025. The following are the fair value changes that were recognized in Q2 Fiscal 2026, and Q2 Fiscal 2025:

			Q2 Fiscal 2026						Q2 Fiscal 2025
Investment in Phylos			$	(216)					$	(1,048)
Investment in OBX			(137)						(67)
Investment in Sanity Group (convertible loan)			(6,239)						(1,678)
Investment in Sanity Group (common shares)			780						(386)
Top-up Rights			(4,307)						(20,487)
Commitment to fund third tranche of Phylos convertible loan			(41)						—
Commitment to issue Preferred Shares			—						(6,266)
Warrants			(2,862)						(2,398)
Preferred shares			(1,502)						(14,825)
			$	(14,524)					$	(47,155)

OTHER NON-OPERATING EXPENSES

Other non-operating expenses of $618 in Q2 Fiscal 2026, increased from $156 in Q2 Fiscal 2025, primarily due to higher foreign currency exchange losses on restricted cash balances.

ADJUSTED EBITDA

Adjusted EBITDA4 was $870 in Q2 Fiscal 2026, compared to $4,908 in Q2 Fiscal 2025. The decrease in adjusted EBITDA compared to the comparative period is primarily due to lower recreational cannabis sales while operating expenses remained flat as a proportion of net revenue. Please refer to the “Financial Results and Review of Operations” section of this MD&A for a reconciliation of adjusted EBITDA to net (loss) income.

NET (LOSS) INCOME

The net loss was $921 in Q2 Fiscal 2026 compared to net income of $42,456 in Q2 Fiscal 2025. The decrease in net income in the current period was primarily attributable to lower fair value gains on derivative liabilities and preferred shares, as well as lower net revenue and gross margins compared to the prior year period. In addition, the current period results were negatively impacted by a $5.8 million impairment loss related to the Company's hemp-derived products business in the U.S.

OUTLOOK

Market Size & Industry Trends

The Company maintains a positive outlook on the cannabis industry, both in Canada and internationally. Recreational cannabis sales in Canada are expected to total $6.1 billion in calendar 20285.

The Canadian market is stabilizing after years of oversupply and pricing pressure. Stabilization has been driven by consolidation, reduced capacity, and the absorption of supply by increased international demand. To address continued increases in international demand, several licensed producers ("LPs") have announced capacity expansion projects. Consumer preferences continue to evolve with sustained demand for high-THC, value-format flower, and rapid growth in the infused pre-roll category.

LPs are increasingly seeking growth in international markets to increase their revenues and margins.

In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment (i.e. November 12, 2026). Non-compliant products will be classified as "marijuana" under the Controlled Substances Act ("CSA") as of the effective date. Organigram’s U.S. offerings will be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that will be impacted by this legislation. Industry efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed,

4 Adjusted EBITDA is a non-IFRS measure. See "Cautionary Statement Regarding Certain Non-IFRS Measures" in this MD&A, and the discussion under the heading “Adjusted EBITDA” and the reconciliation to IFRS measures in the "Financial Results and Review of Operations" section of this MD&A.

5 March 2026 internal modelling using BDSA Analytics Inc. (BDSA) and Hifyre data.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    5

Organigram is actively working to sell, wind-down or otherwise restructure its hemp THC product related activities in the U.S. by November 2026.

Business Outlook

The Company expects to continue pursuing revenue growth through a combination of organic initiatives and strategic acquisitions. Organic growth is expected to be supported by product innovation, improvements in cannabis quality, higher potency offerings, and the commercialization of the Company’s FAST™ nanoemulsion technology in ingestible formats. The Company also expects to focus on growing margin-accretive international sales through its acquisition of Sanity Group, the potential completion of EU-GMP certification at its Moncton facility, and the expansion of branded product sales in international markets. The Company continues to evaluate opportunities in Canada and internationally that may support geographic expansion, entry into new markets, and enhance its long-term strategic positioning.

In Q2 Fiscal 2026, Organigram achieved sequential improvements in international sales and international flower volumes following the partial remediation of international flower product that did not meet international specification requirements, which impacted international sales in Q1 Fiscal 2026, and temporarily slowed international sales growth fiscal year-to-date. The Company continues to progress toward on-spec targets and expects improvements in international sales through the remainder of Fiscal 2026, in addition to strong growth contributions expected from Sanity Group.

The Company originally issued its Fiscal 2026 guidance in Q4 Fiscal 2025, prior to the acquisition of Sanity Group, which closed in April 2026. At that time, the Company contemplated net revenue exceeding $300 million, higher Adjusted Gross Margin6 and Adjusted EBITDA6 relative to Fiscal 2025, positive free cash flow, and capital expenditures of less than $10 million.

Following the acquisition of Sanity Group, which closed in April 2026, we are updating our Fiscal 2026 guidance. Prior to the acquisition, shipments to Sanity Group were recognized as revenue upon shipment to Sanity Group; post-acquisition, shipments to Sanity Group are recognized as revenue upon ultimate sale by Sanity Group to third parties. The Company is now projecting net revenue to exceed $350 million in Fiscal 2026, with Adjusted EBITDA6 and Adjusted Gross Margin6 exceeding Fiscal 2025 performance, free cash flow approximately break even, and capital expenditures of less than $10 million.

Sanity Group continues to deliver strong revenue growth, and the Company re-affirms its previous expectations that Sanity Group revenue will average approximately €25 million per quarter over the next calendar year.

Consistent with industry trends, and Organigram's historical performance, the third and fourth fiscal quarters typically experience seasonal tailwinds, reflecting heightened consumer activity in the summer months and retailer replenishment ahead of the holiday period. This is generally followed by a seasonal slowdown in the first quarter before market demand normalizes.

Our business outlook is subject to a number of assumptions and risk factors as further outlined in the "Cautionary Statement Regarding Forward-Looking Information" section of this MD&A.

International Market

As a result of initiatives aimed at diversifying its international customer base, expanding branded product sales outside Canada, and establishing a presence in the German medical cannabis market through its acquisition of Sanity Group, Organigram expects continued growth in international revenue. Growth is expected to be supported, in part, by the anticipated EU-GMP certification of the Company’s Moncton facility.

In April 2026, the Company provided additional documentation requested by the regulator to support the closure of major findings identified during the certification audit. Given increased regulatory scrutiny of licensed producers seeking EU-GMP certification, the timing of certification remains uncertain; however, the Company expects further updates in the coming months.

Organigram serves a diverse international medical cannabis customer base in Australia, Germany, and the UK. The Company has also completed strategic investments in two U.S.-based companies, OBX and Phylos Bioscience Inc. ("Phylos"). Further, through its acquisition of CPL and launch of the happly brand, Organigram participates in the hemp-derived beverages and edibles segments in the U.S. and is continuing to monitor and prepare to respond to the regulatory developments in this space7.

We continue to monitor and evaluate opportunities in regulated recreational and medical markets outside of Canada, with a focus on the U.S., Europe, and Australia.

All international shipments are subject to the timing and receipt of regulatory approval and an export permit from Health Canada, as well as timing and receipt of regulatory approval and an import permit from the purchasers' regulatory authority.

6Adjusted EBITDA and adjusted gross margin are non-IFRS Measures. See "Cautionary Statement Regarding Certain Non-IFRS Measures" in this MD&A and the discussion under the heading "Adjusted Gross Margin" and the reconciliation to IFRS measures in the "Financial Results and Review of Operations" section of this MD&A.

7See amendments to definition of hemp in the 2018 Farm Bill as described in greater detail in the "Outlook" section of this MD&A

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    6

Jupiter Investment Pool

International expansion initiatives have been supported by the $124.6 million Follow-on BAT Investment, of which $83.0 million was earmarked for the Jupiter Pool.

On April 15, 2026, the Jupiter Pool completed its final capital deployment in connection with the acquisition of Sanity Group.

Prior Jupiter Strategic Investments

On March 26, 2024, the Company completed its inaugural Jupiter Pool investment with a US $2 million investment into U.S.-based OBX.

On June 25, 2024, the Company completed its first European strategic investment, with an approximate $21 million investment into Sanity Group.

KEY DEVELOPMENTS DURING THE QUARTER AND SUBSEQUENT TO MARCH 31, 2026

In February 2026, Organigram announced the expansion of its international product portfolio, with the launch of Edison and BOXHOT medical cannabis vape and pastille products in Australia.

In March 2026, Organigram announced the launch of SHRED Shotz, a compact, single-serve 65ml cannabis beverage powered by FAST™, Organigram’s fast-acting nanoemulsion technology platform designed to deliver a 15-minute onset.

In April 2026, Organigram’s closed the acquisition of Sanity Group, pursuant to the terms of a share purchase agreement dated February 18, 2026. In connection with closing of the acquisition, an indirect wholly owned subsidiary of the Company acquired all of the issued and outstanding shares of Sanity Group not already owned by the Company for an upfront purchase price paid on closing of €107.3 million, consisting of €78.0 million in cash and €29.3 million in share consideration. In connection with the closing of the acquisition, the Company also closed its private placement financing with BAT, for total gross proceeds of €40.3 million (equal to C$65.2 million), and its senior secured credit facilities of up to C$60 million with ATB Financial. In connection with the closing of the acquisition, Mr. Max Konrad Narr was appointed to the Company’s board of directors during the 12-month earnout period ending April 1, 2027. Further details about the acquisition are set out in the Company's press release dated April 15, 2026.

FINANCIAL RESULTS AND REVIEW OF OPERATIONS

CAUTIONARY NOTE REGARDING NON-IFRS FINANCIAL MEASURES

The Company uses certain non-IFRS measures such as adjusted EBITDA, adjusted gross margin and free cash flow in its MD&A and other public documents, which are not measures calculated in accordance with IFRS and have limitations as analytical tools. These performance measures have no prescribed meaning under IFRS, and therefore, amounts presented may not be comparable to similar data presented by other companies. The data is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance such as net income or other data prepared in accordance with IFRS. See the "Cautionary Statement Regarding Certain Non-IFRS Measures" section in this MD&A, and the following discussion.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    7

FINANCIAL HIGHLIGHTS

Below is the period-over-period analysis of the changes that occurred between the six months ended March 31, 2026 and March 31, 2025. Commentary is provided in the pages that follow.

Net revenue is defined as gross revenue, net of customer fees, discounts, rebates, and sales returns and recoveries, less excise taxes. Revenue consists primarily of dried flower and cannabis derivative products sold to the recreational cannabis, medical cannabis, wholesale, and international cannabis markets.

			2026						2025						$ CHANGE						% CHANGE
Financial Results
Gross revenue			$	190,548					$	169,569					$	20,979					12		%
Net revenue			$	123,332					$	108,330					$	15,002					14		%
Cost of sales			$	84,821					$	74,428					$	10,393					14		%
Gross margin before fair value adjustments			$	38,511					$	33,902					$	4,609					14		%
Gross margin % before fair value adjustments			31		%				31		%										—		%
Realized fair value on inventories sold and other inventory charges			$	(38,745)					$	(27,258)					$	11,487					42		%
Unrealized gain on changes in fair value of biological assets			$	39,956					$	25,588					$	14,368					56		%
Gross margin			$	39,722					$	32,232					$	7,490					23		%
Operating expenses			$	58,733					$	46,616					$	12,117					26		%
Loss from operations			$	(19,011)					$	(14,384)					$	4,627					32		%
Other income			$	(38,059)					$	(33,777)					$	(4,282)					13		%
Income tax recovery			$	—					$	(106)					$	(106)					nm
Net income (loss)			$	19,048					$	19,499					$	(451)					(2)		%
Net earnings (loss) per common share, basic			$	0.141					$	0.161					$	(0.020)					(12)		%
Net earnings (loss) per common share, diluted			$	0.139					$	0.155					$	(0.016)					(10)		%
Net cash used in operating activities			$	(22,773)					$	(20,765)					$	2,008					10		%
Adjusted Gross Margin(1)			$	42,296					$	34,614					$	7,682					22		%
Adjusted Gross Margin %(1)			34		%				32		%										2		%
Adjusted EBITDA(1)			$	6,135					$	6,318					$	(183)					(3)		%
Financial Position
Working capital			$	161,341					$	182,879					$	(21,538)					(12)		%
Inventory and biological assets			$	135,158					$	115,049					$	20,109					17		%
Total assets			$	521,312					$	537,903					$	(16,591)					(3)		%
Non-current financial liabilities(2)			$	60,755					$	76,401					$	(15,646)					(20)		%

Note (1): Adjusted gross margin, adjusted gross margin % and adjusted EBITDA are non-IFRS Measures. See "Cautionary Statement Regarding Certain Non-IFRS Measures" and the reconciliation to IFRS measures in the "Financial Results and Review of Operations" section of this MD&A.

Note (2): Non-current financial liabilities excludes non-monetary balances related to contingent share consideration, derivative liabilities and deferred income taxes.

NET REVENUE

For the six months ended March 31, 2026, the Company recorded net revenue of $123,332 compared to net revenue of $108,330 for the six months ended March 31, 2025. Net revenue increased on a period-over-period basis primarily due to an increase in international sales and recreational revenue, as well as the contributions from Motif sales following the acquisition of Motif, for the period from December 6, 2024 to March 31, 2026.

REVENUE COMPOSITION

The Company’s net revenue composition by product category was as follows for the six months ended March 31, 2026 and March 31, 2025:

			2026						2025
Recreational, net of excise duty			104,116						95,218
International flower, edibles and beverages			11,132						9,399
Wholesale, medical and other			8,084						3,713
Total Net Revenue			$123,332						$108,330

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    8

COST OF SALES AND GROSS MARGIN

The gross margin for the six months ended March 31, 2026 was $39,722 compared to $32,232 for the six months ended March 31, 2025. The changes and significant items impacting the six months ended March 31, 2026 were: (i) higher recreational cannabis revenue; and (ii) higher unrealized gains on changes in the fair value of biological assets.

Included in gross margin are the changes in the fair value of biological assets related to IFRS standard IAS 41 – Agriculture. Unrealized gain on changes in the fair value of biological assets for the six months ended March 31, 2026 was $39,956 as compared to $25,588 for the six months ended March 31, 2025.

Cost of sales primarily consists of the following:

•Costs of sales of cannabis (dried flower, pre-rolls, and wholesale/international bulk flower), cannabis extracts, vapes, and other wholesale formats such as extract) include the direct costs of materials and packaging, labour (including any associated share-based compensation), and depreciation of manufacturing building and equipment. This includes cultivation costs (growing, harvesting, drying, and processing costs), extraction, vape filling, quality assurance and quality control, as well as packaging and labelling;

•Costs related to other products, such as vaporizers and other accessories;

•Shipping expenses to deliver product to the customer; and

•The production costs of late-stage biological assets that are disposed of, plants destroyed that do not meet the Company’s quality assurance standards, provisions for excess and unsaleable inventories, provisions related to adjustments to net realizable value that reduce the carrying value of inventory below the original production or purchase cost, and other production overhead.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    9

ADJUSTED GROSS MARGIN

Adjusted Gross Margin is a non-IFRS measure that the Company defines as net revenue less cost of sales, before the effects of: (i) unrealized gains on changes in fair value of biological assets; (ii) realized fair value on inventories sold and other inventory charges; (iii) provisions and impairment of inventories and biological assets; and (iv) provisions to net realizable value. The Company believes that this measure provides useful information to assess the profitability of the Company's operations as it represents the normalized gross margin generated from operations and excludes the effects of non-cash fair value adjustments on inventories and biological assets, which are required by IFRS. See "Cautionary Statement Regarding Certain Non-IFRS Measures". The most directly comparable measure to adjusted gross margin calculated in accordance with IFRS is gross margin before fair value adjustments.

			Q3-F24			Q4-F24			Q1-F25			Q2-F25			Q3-F25			Q4-F25			Q1-F26			Q2-F26
Net revenue			$	41,060		$	44,698		$	42,730		$	65,600		$	70,792		$	80,061		$	63,538		$	59,794
Cost of sales before adjustments			26,474			28,155			28,451			43,679			46,566			49,483			39,683			41,353
Adjusted Gross Margin (1)			14,586			16,543			14,279			21,921			24,226			30,578			23,855			18,441
Adjusted Gross Margin % (1)			36		%	37		%	33		%	33		%	34		%	38		%	38		%	31		%
Less:
Provisions and impairment of inventories and biological assets			628			2,043			13			548			921			1,603			65			3,420
Provisions to net realizable value			71			709			151			—			15			967			273			27
Realized fair value on inventories sold from acquisitions			—			—			—			1,586			867			—			—			—
Gross margin before fair value adjustments			$13,887			$13,791			$14,115			$	19,787		$	22,423		$	28,008		$	23,517		$	14,994
Gross margin % (before fair value adjustments)			34		%	31		%	33		%	30		%	32		%	35		%	37		%	25		%
Add: Realized fair value on inventories sold and other inventory charges			(13,728)			(15,365)			(13,066)			(14,192)			(14,461)			(25,406)			(16,911)			(21,834)
Unrealized gain on changes in fair value of biological assets			13,849			18,790			12,765			12,823			18,184			29,236			16,709			23,247
Gross margin(2)			$	14,008		$	17,216		$	13,814		$	18,418		$	26,146		$	31,838		$	23,315		$	16,407
Gross margin %(2)			34		%	39		%	32		%	28		%	37		%	40		%	37		%	27		%

Note 1: Adjusted gross margin and adjusted gross margin % are non-IFRS measures. See "Cautionary Statement Regarding Certain Non-IFRS Measures" and "Financial Results and Review of Operations" in this MD&A

Note 2: Gross margin reflects the IFRS measure per the Company’s Financial Statements.

Both adjusted gross margin8 and gross margin before fair value adjustments improved throughout Fiscal 2024. This improvement is attributed to several factors, including lower cultivation and post-harvest costs, reduced inventory provisions, lower depreciation resulting from impairment charges recorded in fiscal year 2023 and higher recreational cannabis revenue. In the first quarter of Fiscal 2025, gross margin declined primarily due to lower unrealized gain on changes in fair value of biological assets and lower international sales. In the second quarter of Fiscal 2025, gross margin increased primarily due to the fair value adjustment on inventories acquired through the Motif acquisition and subsequently sold, as required under IFRS. In the third and fourth quarter of Fiscal 2025, the gross margin increase was driven by a higher proportion of international sales with stronger margins, lower cost of sales per unit achieved through greater scale and operating efficiencies (including but not limited to an improvement in yields), and higher unrealized gain on changes in fair value of biological assets, partially offset by lower margins on domestic white label and B2B sales. In Q1 Fiscal 2026, the gross margin declined primarily due to lower unrealized gain on changes in fair value of biological assets. In Q2 Fiscal 2026, the gross margin declined primarily due to changes in product mix, including a lower proportion of higher-margin product categories, and higher product returns.

8 Adjusted EBITDA, adjusted gross margin and adjusted gross margin % are non-IFRS Measures. See "Cautionary Statement Regarding Certain Non-IFRS Measures" and "Financial Results and Review of Operations" in this MD&A.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    10

OPERATING EXPENSES

			2026						2025						CHANGE						% CHANGE
General and administrative			$	29,885					$	26,200					$	3,685					14		%
Sales and marketing			17,665						13,327						4,338						33		%
Research and development			4,109						5,031						(922)						(18)		%
Share-based compensation			1,274						2,058						(784)						(38)		%
Impairment of intangible assets			5,800						—						5,800						100		%
Total operating expenses			$	58,733					$	46,616					$	12,117					26		%

GENERAL AND ADMINISTRATIVE

For the six months ended March 31, 2026, the Company incurred general and administrative expenses of $29,885 compared to $26,200 for the six months ended March 31, 2025. The increased expenses mainly relate to higher depreciation and amortization resulting from the acquisitions of Motif and CPL, as well as increased professional fees, and a credit loss due to a customer insolvency. These expenses as a percentage of net revenue remained flat year over year.

SALES AND MARKETING

For the six months ended March 31, 2026, the Company incurred sales and marketing expenses of $17,665 or 14% of net revenues as compared to $13,327 or 12% of net revenues for the six months ended March 31, 2025. The increased expenses primarily relate to higher investments in advertising, promotions, and trade marketing initiatives to support new product launches in the current period.

RESEARCH AND DEVELOPMENT

Research and development costs of $4,109 for the six months ended March 31, 2026, decreased from $5,031 in the comparative period. The decrease was primarily driven by lower investment in foundational research within the PDC, reflecting a shift toward more targeted, strategic product development, as well as headcount reductions resulting from synergies realized through the Motif acquisition.

SHARE-BASED COMPENSATION

For the six months ended March 31, 2026, the Company recognized $1,274 of share-based compensation expense, compared to $2,058 for the six months ended March 31, 2025. The decrease in expense during the current period is primarily due to cancellation of certain performance share units ("PSUs"), resulting in a reduction in recognized share‑based compensation.

Share-based compensation represents a non-cash expense and was valued using the Black-Scholes valuation model for stock options and using the fair value of the shares on the date of the grant for restricted share units ("RSUs"). The fair value of PSUs was based on the Company’s share price at the grant date, adjusted for an estimate of likelihood of achievement of the defined performance criteria.

IMPAIRMENT OF INTANGIBLE ASSETS

During the six months ended March 31, 2026, the Company identified impairment indicators for one of its two cash-generating units ("CGUs"), primarily due to new regulatory restrictions affecting hemp-derived products in the U.S. These developments reduced expected future revenues, profitability, and cash flows. The Company performed an impairment assessment using a value-in-use model based on a four-year management-approved cash flow forecast. As a result, the recoverable amount of the CGU was determined to be approximately $5,800 below its carrying value, and an impairment charge of $5,800 was recognized during the period.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    11

OTHER (INCOME) EXPENSES

			2026						2025						CHANGE						% CHANGE
Investment income, net of financing costs			$(405)						$(1,004)						$(599)						(60)		%
Acquisition and transaction costs			5,962						5,478						484						9		%
Change in fair value of contingent consideration			(6,619)						(3,899)						(2,720)						(70)		%
Share issuance costs allocated to derivative liabilities			—						170						(170)						(100)		%
Change in fair value of derivative liabilities, preferred shares and other financial assets			(38,916)						(32,660)						(6,256)						19		%
Other non-operating expenses			1,919						(1,862)						3,781						nm
Total other (income)/expenses			$	(38,059)					$	(33,777)					$	(4,282)					13		%

INVESTMENT INCOME, NET OF FINANCING COSTS

Investment income (net of financing costs) of $405 was earned during the six months ended March 31, 2026, compared to $1,004 during the six months ended March 31, 2025. The change in investment income was primarily due to lower average daily cash balances during the current period as compared to the six months ended March 31, 2025.

ACQUISITION AND TRANSACTION COSTS

Acquisition and transaction costs increased to $5,962 for the six months ended March 31, 2026, from $5,478 for the six months ended March 31, 2025. Costs incurred during the six months ended March 31, 2026 primarily related to due diligence, regulatory filings, legal and advisory services, and other transaction-related expenses associated with the acquisition of Sanity Group, as well as severance payments made to employees as part of restructuring initiatives. In contrast, costs incurred in the comparative period were primarily related to due diligence, regulatory filings, legal and advisory services, and integration related expenses associated with the acquisitions of Motif and CPL.

CHANGE IN FAIR VALUE OF CONTINGENT CONSIDERATION

Change in fair value of contingent consideration was a gain of $6,619 for the six months ended March 31, 2026, compared to a gain of $3,899 for the six months ended March 31, 2025. The gain in the current period primarily reflects the derecognition of a contingent consideration of $2,919 previously payable to the former owners of Motif, partially offset by a fair value loss of $3,701 on the revaluation of contingent consideration payable to the former vendors of CPL. In contrast, the gain in the comparative period was primarily driven by the remeasurement of the contingent consideration payable to the former owners of Motif.

CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES, PREFERRED SHARES AND OTHER FINANCIAL ASSETS

Change in fair value of derivative liabilities, preferred shares and other financial assets was a gain of $38,916 for the six months ended March 31, 2026, compared to $32,660 for the six months ended March 31, 2025. The following are the fair value changes that were recognized for the six months ended March 31, 2026, and 2025:

									SIX MONTHS ENDED
															MARCH 31, 2026			0			MARCH 31, 2025
Investment in Phylos															$	2,672		$	—		$	(3,519)
Investment in OBX															(204)			—			(355)
Investment in Sanity Group (convertible loan)															(6,939)			—			(2,829)
Investment in Sanity Group (common shares)															893			—			(339)
Top-up Rights															(16,464)			—			(1,542)
Commitment to fund third tranche of Phylos convertible loan															(11)			—			(304)
Commitment to issue Preferred Shares															—			—			(6,937)
Warrants															(3,724)			—			(5,746)
Preferred shares															(15,139)			—			(11,089)
															$	(38,916)		$	—		$	(32,660)

NET INCOME

Net income for the six months ended March 31, 2026 was $19,048, or $0.141 and $0.139 per Common Share (basic and diluted, respectively), compared to net income of $19,499, or $0.161 per Common Share (basic and diluted, respectively), for the six months ended March 31, 2025. The decrease in net income from the comparative period is primarily attributable to $5.8 million impairment loss related to the Company's hemp-derived products business in the U.S.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    12

SUMMARY OF QUARTERLY RESULTS

			Q3-F24			Q4-F24			Q1-F25			Q2-F25			Q3-F25			Q4-F25			Q1-F26			Q2-F26
Financial Results
Adult-use recreational cannabis revenue (net of excise duty)			$	36,467		$	38,839		$	38,558		$	56,658		$	59,918		$	66,415		$	54,071		$	50,045
Medical international, wholesale and other revenue			$	4,593		$	5,859		$	4,172		$	8,942		$	10,874		$	13,646		$	9,467		$	9,749
Net revenue			$	41,060		$	44,698		$	42,730		$	65,600		$	70,792		$	80,061		$	63,538		$	59,794
Net income (loss)			$	2,818		$	(5,433)		$	(22,957)		$	42,456		$	(6,294)		$	(37,964)		$	19,969		$	(921)
Net earning (loss) per common share, basic			$	0.027		$	(0.050)		$	(0.202)		$	0.329		$	(0.047)		$	(0.283)		$	0.148		$	(0.007)
Net earning (loss) per common share, diluted			$	0.026		$	(0.050)		$	(0.202)		$	0.318		$	(0.047)		$	(0.283)		$	0.146		$	(0.007)
Operational Results
Employee headcount (#)			914			875			1,241			1,150			1,178			1,139			1,137			1,120

During Fiscal 2024, net revenue increased sequentially, primarily driven by higher international sales. In Q1 Fiscal 2025, net revenue decreased modestly, primarily due to lower international sales. In Q2 Fiscal 2025, international sales increased sequentially, alongside growth in recreational net revenue. In Q3 Fiscal 2025, the Company achieved record net revenue, supported by sequential growth in international sales. In Q4 Fiscal 2025, net revenue reached its highest level in the preceding eight quarters. In the first two quarters of Fiscal 2026, net revenue declined due to lower recreational and international sales.

In the third quarter of Fiscal 2024, both net revenue and gross margin increased, resulting in net income. In the fourth quarter of Fiscal 2024, the Company recorded a net loss primarily due to an impairment loss of $4,773 for investments in associates and change in fair value of derivative liabilities and other financial assets (investments which are measured at fair value through profit and loss) of $1,642. In the first quarter of Fiscal 2025, the Company's net loss increased, primarily due to increases in fair value losses on derivative liabilities and higher acquisition and transaction costs related to the acquisition of Motif. In Q2 Fiscal 2025, the Company recorded net income of $42,456. This increase compared to the prior quarter is primarily due to higher gross margins and higher gains from changes in the fair value of derivative liabilities, preferred shares, contingent consideration, and other financial assets. In the third quarter of Fiscal 2025, the Company recorded a net loss of $6,294 primarily due to an increase in fair value losses on derivative liabilities and preferred shares. In the fourth quarter of Fiscal 2025, the Company's net loss increased, primarily due to increases in fair value losses on derivative liabilities and preferred shares. In the first quarter of Fiscal 2026, the Company reported net income of $19,969, primarily due to the higher gains from changes in the fair value of derivative liabilities and preferred shares. In Q2 Fiscal 2026, the Company reported a net loss of $921, primarily attributable to lower gross margins and a reduction in fair value gains on derivative liabilities and preferred shares.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    13

Adjusted EBITDA

Adjusted EBITDA is a non-IFRS measure and the Company calculates Adjusted EBITDA as net income (loss) excluding: investment income, net of financing costs; income tax expense (recovery); depreciation, amortization, impairment, normalization of depreciation add-back due to changes in depreciable assets resulting from impairment charges, (gain) loss on disposal of property, plant and equipment (per the consolidated statement of cash flows); share-based compensation (per the consolidated statement of cash flows); share of loss (gain) from investments in associates including impairment loss; change in fair value of contingent consideration; change in fair value of derivative liabilities, preferred shares and other financial assets; expenditures incurred in connection with R&D activities (net of depreciation); unrealized (gain) loss on changes in fair value of biological assets; realized fair value on inventories sold and other inventory charges; provisions and net realizable value adjustments related to inventory and biological assets; government subsidies, insurance recoveries and other non-operating expenses (income); legal provisions (recoveries); incremental fair value component of inventories sold from acquisitions; ERP implementation costs; transaction costs; share issuance costs; and provision for expected credit losses. Management believes that Adjusted EBITDA is intended to provide a proxy for the Company’s operating cash flow and derives expectations of future financial performance for the Company, and excludes adjustments that are not reflective of current operating results. See "Cautionary Statement Regarding Certain Non-IFRS Measures". The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is net income (loss).

During the second quarter of Fiscal 2024, management changed the calculation of Adjusted EBITDA to include provisions for expected credit losses and has conformed prior quarters accordingly.

Adjusted EBITDA (Non-IFRS Measure)
Adjusted EBITDA Reconciliation			Q3-F24			Q4-F24			Q1-F25			Q2-F25			Q3-F25			Q4-F25			Q1-F26			Q2-F26
Net (loss) income as reported			$	2,818		$	(5,433)		$	(22,957)		$	42,456		$	(6,294)		$	(37,964)		$	19,969		$	(921)
Add/(deduct):
Investment income, net of financing costs			(1,179)			(960)			(825)			(179)			(73)			(73)			(93)			(312)
Income tax expense (recovery)			—			30			—			(106)			(9,903)			(3,761)			—			—
Depreciation and amortization			3,039			3,073			3,387			4,839			4,789			4,960			4,980			5,033
Impairment of property, plant and equipment, intangible assets and goodwill			—			—			—			—			—			—			—			5,800
ERP implementation costs			7			465			744			628			1,217			951			407			120
Acquisition and transaction costs			421			74			4,504			974			654			448			1,606			4,356
Inventory and biological assets fair value and NRV adjustments			578			(673)			465			1,917			(2,787)			(1,260)			540			2,034
Incremental fair value component on inventories sold from acquisitions			—			—			—			1,586			897			—			—			—
Share-based compensation			2,087			1,093			1,325			938			1,007			947			770			728
Other (income) expenses(1)			(6,687)			6,646			12,477			(50,728)			13,511			42,539			(24,900)			(18,716)
Provision for non-recurring credit losses			—			—			—			—			—			—			—			821
Research and development expenditures, net of depreciation			2,381			1,545			2,290			2,583			2,676			3,056			1,986			1,927
Adjusted EBITDA			$	3,465		$	5,860		$	1,410		$	4,908		$	5,694		$	9,843		$	5,265		$	870
Divided by: net revenue			41,060			44,698			42,730			65,600			70,792			80,061			63,538			59,794
Adjusted EBITDA Margin % (Non-IFRS Measure)			8		%	13		%	3		%	7		%	8		%	12		%	8		%	1		%

Note (1):    Other (income) expenses(1) includes share of loss from investments in associates, (gain) loss on disposal of property, plant and equipment, change in fair value of derivative liabilities, preferred shares, contingent consideration and other financial assets, and certain other non-operating (income) expenses.

In the third quarter of Fiscal 2024, the Company's adjusted EBITDA was $3,465. In fourth quarter of Fiscal 2024, as a result of higher recreational cannabis revenue and a higher Adjusted Gross Margin resulting from lower cultivation and post-harvest costs, Adjusted EBITDA increased to $5,860. During the first quarter of Fiscal 2025, the Adjusted EBITDA decreased to $1,410 mainly due to lower international sales. In Q2 Fiscal 2025, the Company's international sales increased and the Adjusted EBITDA increased to $4,908. During third quarter of Fiscal 2025, the Company's recreational and international sales increased, resulting in an increase in Adjusted EBITDA to $5,694. In fourth quarter of Fiscal 2025, continued growth in net revenues and lower costs of production (on a per unit basis), resulted in Adjusted EBITDA of $9,843. During the first quarter of Fiscal 2026, Adjusted EBITDA decreased to $5,265 due to lower international and recreational sales, partially offset by the realization of cost savings initiatives.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    14

In Q2 Fiscal 2026, Adjusted EBITDA decreased to $870 due to lower recreational revenue while operating expenses remained flat as a proportion of net revenue, as well as the impact of higher returns provisions.

BALANCE SHEET, LIQUIDITY AND CAPITAL RESOURCES

The following represents selected balance sheet highlights of the Company as at March 31, 2026 and September 30, 2025:

			MARCH 31, 2026						SEPTEMBER 30, 2025						% CHANGE
Cash, restricted cash and short-term investments			$	54,754					$	84,420					(35)		%
Inventories			$	117,928					$	106,023					11		%
Working capital			$	161,341					$	158,738					2		%
Total assets			$	521,312					$	562,211					(7)		%
Non-current financial liabilities(1)			$	60,755					$	76,401					(20)		%
Total shareholders' equity			$	371,812					$	349,130					6		%

Note 1: Non-current financial liabilities excludes non-monetary balances related to contingent share consideration, derivative liabilities and deferred income taxes.

On March 31, 2026, the Company had total cash (including restricted cash and short-term investments) of $54,754 compared to $84,420 at September 30, 2025. The decrease is primarily due to an increase in non-cash working capital (per the consolidated statement of cash flows) of $16,815, purchase of property, plant and equipment of $2,327 and an additional investment of $4,127 in Phylos during the current period.

Subsequent to Q2 Fiscal 2026, the Company utilized the majority of its reported cash position to fund the acquisition of Sanity Group and entered into a $60 million senior secured credit facility to maintain liquidity and financial flexibility. The facility consists of: (i) a $20 million non-revolving term facility, used to partially fund the acquisition of Sanity Group; (ii) a $30 million revolving credit facility and (iii) a $10 million operating facility for general corporate purposes. Following the acquisition of Sanity Group and establishment of the credit facility, management believes the Company maintains sufficient liquidity and financial flexibility to fund operations, meet working capital requirements, and support planned growth initiatives over the medium term.

The Company's cash balances fluctuate significantly on a quarterly basis due to the timing of excise duty remittances. Management continues to evaluate financing alternatives to support strategic growth initiatives. Subject to prevailing market conditions and any required consents and approvals under the Investor Rights Agreement and the Credit Facilities, the Company may access additional financing, if required. The Common Shares are listed for trading on both the NASDAQ and TSX, and there is analyst coverage among sell-side brokerages. However, there can be no assurance that capital will be available on acceptable terms, or at all.

The following highlights the Company’s cash flows during the three and six months ended March 31, 2026 and March 31, 2025:

			THREE MONTHS ENDED												SIX MONTHS ENDED
			MARCH 31, 2026						MARCH 31, 2025						MARCH 31, 2026						MARCH 31, 2025
Cash provided by (used in):
Operating activities			$	(6,760)					$	(16,585)					$	(22,773)					$	(20,765)
Financing activities			(451)						40,660						(901)						40,458
Investing activities			(1,411)						(10,299)						(5,755)						(71,852)
			$	(8,622)					$	13,776					$	(29,429)					$	(52,159)
Effect of foreign exchange on cash			$	404					40						$	(222)					2,054
Net cash used			$	(8,218)					$	13,816					$	(29,651)					$	(50,105)
Cash position
Beginning of period			62,161						68,684						83,594						132,605
End of period			$	53,943					$	82,500					$	53,943					$	82,500
Short-term investments			811						873						811						873
Cash (including restricted cash) and short-term investments			$	54,754					$	83,373					$54,754						$83,373

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    15

Cash used in operating activities for the three months ended March 31, 2026 was $6,760 compared to cash used of $16,585. The decrease in cash used in operating activities for the current period is primarily due to a decrease in working capital during the current period.

Cash used in operating activities for the six months ended March 31, 2026 was $22,773 compared to cash used of $20,765. The increase in cash used in operating activities for the current period is primarily due to an increase in working capital during the current period.

Cash (used in) provided by financing activities for the three and six months ended March 31, 2026 was $(451) and $(901), respectively. In comparison, for the three and six months ended March 31, 2025, cash provided by financing activities was $40,660 and $40,458, respectively. The increase in cash used in financing activities for the three and six months ended March 31, 2026 is primarily due to an increase in lease payments in the current period.

Cash used in investing activities for the three and six months ended March 31, 2026 was $1,411 and $5,755, respectively. In comparison, for the three and six months ended March 31, 2025, cash used in investing activities was $10,299 and $71,852. The decrease in cash used in investing activities is primarily due to the acquisition of Motif and CPL, which was completed in the comparative period.

Free Cash Flow

Free cash flow is a non-IFRS measure and is calculated by the Company as net cash provided by or used in operating activities less the purchase of property, plant and equipment. Management believes that free cash flow is a useful indicator of the Company's capacity to fund operations from internally generated cash flows, without the need for additional borrowings or use of existing cash reserves under normal operating conditions. See "Cautionary Statement Regarding Certain Non-IFRS Measures". The most directly comparable measure to free cash flow in accordance with IFRS is net cash and restricted cash provided by (used in) operating activities.

			SIX MONTHS ENDED
			MARCH 31, 2026						MARCH 31, 2025
Net cash and restricted cash used in operating activities			$	(22,773)					$	(20,765)
Deduct:
Purchase of property, plant and equipment			(2,327)						(8,134)
Free cash flow			$	(25,100)					$	(28,899)

Free cash flow for the six months ended March 31, 2026 was $(25,100). In comparison, for the six months ended March 31, 2025, free cash used flow was $(28,899). The decrease in free cash flow is primarily due to the decrease in purchase of property, plant and equipment.

OFF BALANCE SHEET ARRANGEMENTS

There were no off-balance sheet arrangements during the three and six months ended March 31, 2026.

RELATED PARTY TRANSACTIONS

MANAGEMENT AND BOARD COMPENSATION

Key management personnel are those persons having the authority and responsibility for planning, directing, and controlling activities of the Company, directly or indirectly. The key management personnel of the Company are the members of the Company’s executive management team and Board of Directors. The transactions are conducted at arm's length and in the normal course of operations.

For the three and six months ended March 31, 2026 and March 31, 2025, the Company’s expenses included the following management and Board of Directors compensation:

			THREE MONTHS ENDED												SIX MONTHS ENDED
			MARCH 31, 2026						MARCH 31, 2025						MARCH 31, 2026						MARCH 31, 2025
Salaries and bonus			$	1,617					$	1,324					$	2,994					$	2,626
Share-based compensation			511						646						987						1,421
Total key management compensation			$	2,128					$	1,970					$	3,981					$	4,047

During the three and six months ended March 31, 2026, nil and 650,061 RSUs (March 31, 2025 – nil and 404,905), respectively were granted to key management personnel with an aggregate fair value of $nil and $1,586 (March 31, 2025 – $nil and $1,538), respectively. In addition, for the three and six months ended March 31, 2026, nil and 379,254 PSUs (March 31, 2025 – nil and

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    16

404,905), respectively, were issued to key management personnel with an aggregate fair value of $nil and $925 (March 31, 2025 – $nil and $457), respectively.

SIGNIFICANT TRANSACTIONS WITH ASSOCIATES AND JOINT OPERATIONS

The Company has transactions with related parties, as defined in IAS 24 Related Party Disclosures, all of which are undertaken in the normal course of business.

For the three and six months ended March 31, 2026, under the product development collaboration agreement between the Company and BAT dated March 10, 2021, BAT incurred $675 and $1,350 (March 31, 2025 – $824 and $1,242), respectively, of direct expenses and the Company incurred $1,080 and $2,307 (March 31, 2025 – $1,450 and $2,924), respectively, of direct expenses and capital expenditures of $nil and $nil (March 31, 2025 – $nil and $nil), respectively, related to the Center of Excellence. The Company recorded in the three and six months ended March 31, 2026, $877 and $1,828 (March 31, 2025 – $1,137 and $2,083), respectively of these expenditures within research and development expenses in the condensed consolidated interim statements of operations and comprehensive (loss) income. For the three and six months ended March 31, 2026, the Company recorded $0 and $0 (March 31, 2025 – $nil and $nil), respectively, of capital expenditures which are included in the condensed consolidated interim statements of financial position.

At March 31, 2026, there is a balance receivable from BAT of $971 (September 30, 2025 – $2,001).

In November 2023, the Company entered into a subscription agreement with BAT for a $124.6 million follow-on BAT investment, whereby BAT, agreed to subscribe for a total of 38,679,525 Common Shares and Preferred Shares (the "Shares") at a price of $3.2203 per Share, subject to the receipt of shareholder approval, certain regulatory approvals and other conditions. On February 28, 2025, the Company closed the third and final tranche of the follow-on BAT investment and issued 7,562,447 Common Shares and 5,330,728 Preferred Shares of the Company.

FAIR VALUE MEASUREMENTS

(i) Financial Instruments

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The Company categorizes its fair value measurements according to a three-level hierarchy. The hierarchy prioritizes the inputs used by the Company’s valuation techniques. A level is assigned to each fair value measurement based on the lowest-level input significant to the fair value measurement in its entirety.

The three levels of the fair value hierarchy are described as follows:

•level 1 inputs are quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date;

•level 2 inputs, other than quoted prices included within level 1, that are observable for the asset or liability, either directly or indirectly; and

•level 3 inputs are unobservable inputs for the asset or liability.

As at March 31, 2026, the Company held financial instruments that are measured at fair value at each reporting date. The valuation of these instruments is performed using various models, which, due to the complexity and nature of the instruments, primarily rely on Level 3 inputs within the fair value hierarchy. These inputs are unobservable and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the instruments. Refer to Note 17 of the Interim Financial Statements for further information.

(ii) Biological Assets

Biological assets, consisting of cannabis plants, are measured at fair value less costs to sell in accordance with the IFRS as issued by the IASB. The fair value measurement is categorized within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. These inputs include expected yield per plant, average selling price (net of post-harvest costs), wastage rates, post-harvest processing costs, and the stage of growth of the plants at the reporting date. Changes in these assumptions could result in significant variations in the fair value of biological assets. Refer to Note 6 of the Interim Financial Statements for further information.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    17

OUTSTANDING SHARE DATA

(i) Outstanding Shares, Warrants and Options and Other Securities

The following table sets out the number of Common Shares, preferred shares, options, warrants, Top-up Rights, RSUs and PSUs outstanding of the Company as at March 31, 2026 and May 7, 2026.

			MARCH 31, 2026						MAY 7, 2026
Common shares issued and outstanding			136,468,690						140,775,022
Preferred shares(1)			13,794,163						49,204,022
Options			2,130,008						2,802,508
Warrants			4,450,500						4,450,500
Top-up Rights			18,725,700						6,127,329
Restricted share units			3,178,036						3,464,011
Performance share units			1,946,399						2,013,771
Total fully diluted shares			180,693,496						208,837,163

Note 1: The preferred shares are eligible, under certain scenarios, to be converted into common shares equaling 15,263,430 consisting of the original preferred shares of 13,794,163 that convert into one common share and accretion amounts that accrue to the preferred shares at an annual rate of 7.5% per annum. Since the preferred shares were issued under the second and third tranches of the Follow-On BAT Investment, they have collectively accrued 1,469,267 of additional common share conversion value.

CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The preparation of the Financial Statements under IFRS requires management to make judgments, estimates, and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

There have been no changes in the Company's critical accounting estimates during the three months ended March 31, 2026. For additional information on the Company’s accounting policies and key estimates, refer to the note disclosures in the Annual Financial Statements and MD&A as at and for the year ended September 30, 2025.

Adoption of New Accounting Pronouncements

Amendment to IAS 21: Lack of Exchangeability
In August 2023, the IASB amended IAS 21 to clarify when a currency is exchangeable into another currency and how a company estimates a spot rate when a currency lacks exchangeability. The amendments are effective for annual reporting periods beginning on or after January 1, 2025. The Company’s international transactions are limited to a few countries, such as the United States, the United Kingdom, Australia and Germany. These countries all have active markets for their currencies and therefore, there is no risk of a lack of exchangeability for these currencies.

These amendments do not have any material impact on the Company’s consolidated financial statements.

CONTINGENT LIABILITIES

The Company recognizes loss contingency provisions for probable losses when management can reasonably estimate the loss. When the estimated loss lies within a range, the Company records a loss contingency provision based on its best estimate of the probable loss. If no particular amount within that range is a better estimate than any other amount, the mid-point of the range is used. As information becomes known a loss contingency provision is recorded when a reasonable estimate can be made. The estimates are reviewed at each reporting date and the estimates are changed when expectations are revised. An outcome that deviates from the Company’s estimate may result in an additional expense or release in a future accounting period.

DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING

In accordance with National Instrument 52-109 - Certification of Disclosure in Issuers’ Annual and Interim Filings (“NI 52-109”) and Rule 13a-15 under the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), management is responsible for establishing and maintaining effective Disclosure Controls and Procedures (“DCP”) and Internal Control over Financial Reporting (“ICFR”).

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    18

As previously disclosed in the Company’s Annual Report on Form 40-F for the year ended September 30, 2025, management identified a material weakness in ICFR, and the Company’s independent registered public accounting firm issued an adverse opinion on the effectiveness of the Company’s ICFR as of that date.

DISCLOSURE CONTROLS AND PROCEDURES

The Company maintains a set of DCP designed to provide reasonable assurance that information required to be publicly disclosed is recorded, processed, summarized and reported on a timely basis. As required by NI 52-109 and Exchange Act Rule 13a-15(b), an evaluation of the design and operation of our DCP was completed prior to the date of this MD&A under the supervision and with the participation of management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"). The evaluation was conducted using the criteria set forth in Internal Control - Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO 2013 Framework”). Based upon this evaluation, our CEO and CFO concluded that, because of the material weaknesses in our ICFR described below, our DCP were not effective as of such date.

INTERNAL CONTROL OVER FINANCIAL REPORTING

NI 52-109 requires the CEO and CFO to certify that they are responsible for establishing and maintaining ICFR for the Company and that those internal controls have been designed and are effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with IFRS. Similarly, Exchange Act Rule 13a-15(c) requires the Company's management, with the participation of the CEO and CFO, to evaluate ICFR as of the end of the fiscal year. The CEO and CFO are also responsible for disclosing any changes to the Company’s internal controls during the most recent period that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.

LIMITATIONS ON SCOPE OF DESIGN

The Company has limited the scope of its evaluation of DCP and ICFR to exclude controls, policies and procedures over entities that were acquired by the Company not more than 365 days before the end of the financial period. The only entities controlled by the Company but that were scoped out of the evaluation of DCP and ICFR were CPL and Organigram USA Inc. (both acquired effective March 31, 2025).

Excluding goodwill and intangible assets, CPL constitutes approximately $2,523 of the Company’s current assets, $2,523 of total assets, $1,097 of current liabilities and $5,030 of total liabilities as of the acquisition date.

MATERIAL CHANGES TO INTERNAL CONTROL OVER FINANCIAL REPORTING

In the second quarter of Fiscal 2026, management, with oversight from the Audit Committee, implemented remediation measures related to the material weaknesses identified as at September 30, 2025 as outlined below in the "Status of Remediation Plan" section.

MANAGEMENT’S EVALUATION OF INTERNAL CONTROL OVER FINANCIAL REPORTING

The Company’s management, under the supervision and with the participation of its CEO and CFO, conducted an evaluation of the effectiveness of the Company’s ICFR as defined by NI 52-109 and Rule 13a-15(f) of the Exchange Act as of December 31, 2025, using the criteria set forth by the COSO 2013 Framework. Based on this evaluation, management concluded that the Company's ICFR was not effective as of December 31, 2025.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weakness:

•Management review controls designed to ensure the completeness and accuracy of complex spreadsheets used in the biological assets and inventory valuation processes.

STATUS OF REMEDIATION PLAN

The Company made progress in remediating the material weakness related to the Ample system and other control deficiencies discussed above under “Material Changes to Internal Control Over Financial Reporting” as at the end of Fiscal 2025. Specifically, controls related to user access rights and related controls over the Company’s inventory management application, the Ample system, were not designed or operating effectively. This component of the material weakness was remediated through the decommissioning of the Ample system in the first quarter of Fiscal 2026, and the system application is no longer in use.

Management, with the assistance of external and internal specialists, has continued reviewing and revising its ICFR and remains committed to implementing changes to ensure that the con

The following remedial activities remain in progress as at the date of this MD&A and are expected to continue at least throughout the latter half of Fiscal 2026. The controls associated with these remedial activities have not yet been subject to control testing to conclude on their design or operational effectiveness.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    19

•The Company will continue to streamline complex spreadsheet models related to biological assets and inventory to reduce the risk of errors in mathematical formulas and improve the ability to verify the logic of complex spreadsheets, while continuing to automate processes, and leverage the Company's new inventory costing upgrades in its ERP system.

Following the improvement of the material weakness related to IT General Controls, senior management has discussed the remaining material weakness with the Audit Committee which will continue to review progress on these remediation activities. While we believe these actions, including the third phase of the ERP system, will contribute to the remediation of the material weakness, we have not yet completed all of the corrective processes, procedures and related evaluation or remediation that we believe are necessary. As we continue to evaluate and work to remediate the remaining material weakness, we may need to take additional measures to address the deficiencies. Until the remediation steps set forth above, including efforts to implement any additional control activities identified in the process, are fully implemented and operate for a sufficient period of time to conclude that they are operating effectively, the remaining material weakness described above will not be considered fully remediated. While significant progress has been made toward remediation of the remaining material weakness, no assurance can be provided at this time that the actions and remediation efforts will effectively remediate the remaining material weakness described above or prevent the incidence of other material weaknesses in the Company’s ICFR in the future. Management expects to fully remediate the remaining material weakness identified before the end of Fiscal 2026. See “Risk Factors” in this MD&A and in the Company's annual information form for the year ended September 30, 2025 ("AIF").

Management, including the CEO and CFO, does not expect that DCP or ICFR will prevent all misstatements, even as the remediation measures are implemented and further improved to address the material weakness. The design of any system of internal controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving the stated goals under all potential future conditions.

RISK FACTORS

The Company’s business is subject to risks inherent in a high-growth, heavily regulated industry. We have identified certain risks pertinent to our business that may have affected or may affect our business, financial conditions, results of operations and cash flows, as further described in this MD&A. For additional risk factors, readers are directed to the discussion under "Risk Factors" in the AIF, which is (a) available under the Company’s issuer profile on SEDAR+ at www.sedarplus.com, and (b) incorporated into and forms part of the Company's annual report on Form-40F filed on EDGAR at www.sec.gov. Management attempts to assess and mitigate any risks and uncertainties by retaining experienced professional staff and ensuring that the Board of Directors and senior management of the Company are monitoring the risks impacting or likely to impact the business on a continuous basis.

(i) Credit Risk

Credit risk arises from deposits with banks, short-term investments, outstanding trade and other receivables, restricted cash and other financial assets. For trade receivables, the Company does not hold any collateral as security but mitigates this risk by dealing only with what management believes to be financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance. For other receivables, outside of the normal course of business, management generally obtains guarantees and general security agreements. The maximum exposure to credit risk of cash, short-term investments, restricted cash, other financial assets and accounts receivable and other receivables on the statement of financial position at March 31, 2026 approximates $165,273 (September 30, 2025 – $198,827).

As of March 31, 2026 and September 30, 2025, the Company’s aging of trade receivables was as follows:

			MARCH 31, 2026						SEPTEMBER 30, 2025
0-90 days			$	45,573					$	56,442
More than 90 days			12,341						12,846
Gross trade receivables			$	57,914					$	69,288
Less: Expected credit losses and reserve for product returns and price adjustments			(6,293)						(5,703)
			$	51,621					$	63,585

(ii) Liquidity Risk

The Company’s liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company manages its liquidity risk by reviewing its capital requirements and liquidity position on an ongoing basis. At March 31, 2026, the Company had $4,292 (September 30, 2025 – $28,200) of cash (unrestricted) and working capital of $161,341 (September 30, 2025 – $158,738). Further, the Company may potentially access financing through the capital markets if required, although there can be no assurance that capital will be available on terms acceptable to the Company or at all.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    20

Subsequent to March 31, 2026, the Company completed the acquisition of Sanity Group and related financing transactions, including a private placement and the establishment of senior secured credit facilities. These transactions are expected to strengthen the Company’s liquidity position and provide additional funding capacity to support ongoing operations and integration activities. If necessary, the Company may access additional liquidity through the capital markets, including both debt and equity financing.

The Company is obligated to the following contractual maturities relating to their undiscounted cash flows as at March 31, 2026:

			Carrying Amount			Contractual Cash Flows			Less than 1 year			1 to 3 years			3 to 5 years			More than 5 years
Accounts payable and accrued liabilities			$	73,139		$	73,139		$	73,139		$	—		$	—		$	—
Lease obligations			8,198			10,478			1,531			3,197			2,818			2,932
			$	81,337		$	83,617		$	74,670		$	3,197		$	2,818		$	2,932

The contractual maturities noted above are based on contractual due dates of the respective financial liabilities.

In connection with the Company’s facilities, the Company is contractually committed to approximately $930 of capital expenditures.

(iii) Market Risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk for the Company is comprised of interest rate risk, which is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates relates primarily to the Company’s debt obligations with a floating interest rate. The Company has determined that a 1% change in rates would not have a material impact on the consolidated financial statements.

(iv) Concentration Risk

The Company’s accounts receivable are primarily due from provincial government agencies (four of which, individually, represented more than 10% of the Company’s revenues during the three months ended March 31, 2026), with the remaining material accounts receivable balance due from an international customer. The provincial government agencies and the international customer are considered creditworthy, and management believes that the entire accounts receivable balance is collectible.

(v) Risks of significant changes or developments with respect to domestic and international customs, tariffs, and trade policies, corresponding or retaliatory actions by other countries and related uncertainties

Significant changes or developments with respect to domestic and international customs, tariffs, and trade policies in the geographies where the Company operates, any corresponding or retaliatory actions taken, and related uncertainties could have an adverse effect on the Company's financial results and profitability. Since the inauguration of the current U.S. president on January 20, 2025, the U.S. has imposed a number of tariffs on exports from Canada and other countries to the U.S. The international trade disputes sparked by the tariffs imposed or potential tariffs to be imposed by the U.S. and any other future actions taken by the U.S. and other countries in response, including a further escalation in tariffs, and/or the withdrawal from, or changes to, international trade agreements or policies related to international commerce, are expected to have a negative impact on the Canadian economy and other markets where the Company operates, and could adversely affect the Company’s business operations and financial condition. In addition, the uncertainty as to whether additional tariffs or trade policies will be adopted domestically or internationally and the uncertainty of the impact of such tariffs and trade policies have and may continue to have negative impact on the Canadian and global economy and may adversely affect the Company’s business operations and financial condition.

(vi) Risks related to third party data

The Company relies on independent third party data for market share position and there is no assurance third party data provides an accurate representation of actual sales as some third parties use different methodologies or calculations to estimate market share position, and because market and industry data is inherently imprecise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey or data collection process. The Company also relies on its own market research and internal data with the view to testing the reliability of such third-party data but the Company's ability to determine the accuracy of such third-party data remains limited.

(vii) Risks related to international sales and operations

The Company sells hemp-derived products in the U.S. and exports cannabis to a number of countries whose laws vary, and many are unsettled and still developing. There is no assurance that the Company will continue to meet the evolving legal and regulatory

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    21

requirements applicable to each international jurisdiction. Any change in laws or regulations may adversely impact the Company’s ability to export its products or continue doing business in the U.S or any other international jurisdictions.

The Changing Legal Status of Hemp-Derived Products in the United States

The Company owns or invests in certain entities in the U.S, including a cannabis and hemp genetics licensing company, a hemp processor, and a hemp beverage and edibles company. While these entities currently comply with U.S. laws, such laws are frequently changing, and any widespread enforcement against the entities or the entities’ customers could negatively impact the Company’s business operations and financial condition.

In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment (i.e. November 12, 2026). Non-compliant products will be classified as "marijuana" under the CSA as of the effective date. Organigram’s U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that may be impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. State legislative and regulatory responses are ongoing, though uneven with broad uncertainty. Certain states (for example, New Jersey9 and Missouri10) have enacted legislation aligning state law with the new federal definition of hemp, though with differing implementation timelines for such changes. The majority of states' hemp laws and related regulatory regimes remain unchanged.

Several bills have been introduced in Congress, including, among others, the American Hemp Protection Act of 2025 (H.R. 6209), which would repeal Section 781 in its entirety and restore the 2018 Farm Bill definition, and the Hemp Planting Predictability Act (H.R. 7024), which would extend by two years the implementation of changes to the regulation of hemp products11. As of the date of this filing, no legislative proposals have been enacted, and there can be no assurance that any repeal, delay, or replacement legislation will be adopted before the November 12, 2026 effective date. If current federal legislation is not amended or reversed, Organigram may have to sell, wind-down or otherwise restructure its hemp THC product related activities in the U.S. by November 2026. In addition to federal uncertainty, unforeseen regulatory obstacles or compliance costs may hinder our ability to successfully compete in the market for such products, which could adversely impact our business, operating results, financial condition, brand and reputation.

The Company competes with other hemp THC products, state-legal cannabis products and products available in the illicit market, and the public is often uninformed about the differences of these markets. We test all of our products for safety and quality. However, many of our competitors in the market may not do so. Because our business is dependent, in part, upon continued market acceptance of THC by consumers, any negative trends relating to cannabis or hemp could adversely affect our business operations. For example, consumers may hear about negative health or safety outcomes for a competitor’s product and ascribe those outcomes to the entire category. Negative views of the category caused by third parties may hinder our ability to successfully market our products, or lead to new laws or regulations that prohibit or limit the sale of such products, which could adversely impact our business, operating results, financial condition, brand and reputation.

On December 18, 2025, President Trump issued an Executive Order ("EO") directing that cannabis be rescheduled from schedule I to schedule III. On April 22, 2026, Acting Attorney General Todd Blanche signed a final order (the "Final Order") transferring (i) U.S. Food and Drug Administration-approved cannabis products and (ii) cannabis subject to a qualifying state-issued medical cannabis license from schedule I to schedule III of the CSA, effective immediately12. This action was taken under the Attorney General's authority, pursuant to 21 U.S.C. § 811(d)(1), to reschedule drugs to carry out U.S. treaty obligations under the 1961 Single Convention on Narcotic Drugs13, which permitted the order to go into immediate effect without notice-and-comment rulemaking. This represents a significant, formal acknowledgement that cannabis has medical value and less potential for abuse than schedule I and II controlled substances. The Drug Enforcement Administration (“DEA”) has simultaneously issued a notice of hearing on proposed rulemaking announcing an expedited administrative hearing (starting June 29, 2026) to consider whether cannabis as a whole—including adult-use cannabis—should be rescheduled from schedule I to schedule III through the formal rulemaking process14. According to the hearing notice, the administrative proceeding will conclude no later than July 15, 2026. The outcome of that proceeding is not guaranteed, and any final rule extending rescheduling beyond the medical-only category could take several months (or longer) after the hearing concludes.

Because cannabis remains a controlled substance, it is still subject to the CSA's requirements, including registration with the DEA. In that regard, the Final Order establishes an expedited DEA registration pathway for state-licensed medical cannabis

9 See S4509 (2026), codified as P.L. 2025, c. 215.

10 See HB 2641 (2026).

11 Additionally, in late April, 2026, the U.S. House of Representatives passed the Farm, Food, and National Security Act of 2026 (H.R. 7567; the “2026 Farm Bill”), which includes provisions aimed at reducing regulatory burdens for producers of industrial hemp but does not include any language to delay or alter the hemp-derived THC product ban. The Senate is expected to consider its own version of the 2026 Farm Bill in the coming weeks.

12 Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements, 91 Fed. Reg. 22714 (April 28, 2026).

13 See United Nations Single Convention on Narcotic Drugs, Mar. 30, 1961, 18 U.S.T. 1407, 520 U.N.T.S. 151, as amended by the 1972 Protocol.

14 Schedules of Controlled Substances: Rescheduling of Marijuana, 91 Fed. Reg. 22777 (April 28, 2026).

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    22

manufacturers, distributors, and dispensers. Applications submitted within 60 days of the Federal Register publication date (i.e., by approximately June 27, 2026) will benefit from an expedited review process, and applicants filing within that window may continue operating under their state licenses during the pendency of their application.

The rescheduling may have far-reaching implications that are not yet fully understood, including for hemp and hemp THC products. Of significant note, the Final Order does not address the role of the U.S. Food and Drug Administration (“FDA”) and the treatment of cannabis sold as foods, dietary supplements, or unapproved drugs under the Federal Food, Drug, and Cosmetic Act (FDCA). Moreover, the Final Order faces meaningful litigation risk. Among other things, opponents will likely challenge the use of treaty-obligation authority to bypass formal rulemaking and the rescheduling’s underlying scientific bases.

Regardless, the Final Order has effectively legalized, under federal law, all medical cannabis that is subject to a state medical cannabis license and the interstate commerce of such cannabis so long as it occurs within DEA-registered channels. Given this material change in federal legality, the Company is now reviewing all options for entering the U.S. medical cannabis market15.

Finally, the EO also directed White House staff to work with Congress to “update the statutory definition” of hemp to allow Americans to access CBD products while permitting Congress to “restrict the sale of products posing serious health risks,” and to consult with relevant executive branch departments to “develop a regulatory framework for hemp-derived cannabinoid products, including development of guidance on an upper limit on milligrams of THC per serving with considerations on per container limits and CBD to THC ratio requirements.” As of the date of this filing, it remains unclear whether this will be achieved, including whether, again, Congress—which recently revised the definition of hemp in the Continuing Appropriations and Extensions Act to permit no more than 0.4 milligrams of THC per container—will agree to further changes. The regulatory volatility creates significant uncertainty for our business of selling hemp THC products and our other U.S. hemp-related investments. Moreover, and as noted above, if current federal legislation is not amended or reversed, Organigram may have to sell, wind-down or otherwise restructure its hemp THC product related activities in the U.S. by November 2026.

(ix) Geopolitical Conflicts Risk

Political instability, acts of terrorism, war (including the outbreak of armed conflict involving Iran, the war between the terrorist organization Hamas and Israel, and the war in Ukraine) or other conflicts and other events outside of the Company’s control, may adversely impact its business and operating results. Recently, the U.S. – Israeli war with Iran has resulted in a significant increase in tension in the region and disruptions to regional energy markets, supply chains, and key shipping routes, including the Strait of Hormuz, a critical global oil transit corridor, and may continue to have far reaching effects on the global economy. Such effects on the global economy have produced downward pressure on share prices and on the availability of credit while also driving up interest rates, further complicating borrowing and lending activities. If current levels of market disruption and volatility continue or increase, the Company might experience reductions in business activity, increases in funding costs, decreases in asset values, additional write-downs and impairment charges and lower profitability. In addition to the direct impact that such events could have on the Company’s facilities and workforce, these types of events could negatively impact consumer spending in the impacted regions or depending on the severity, globally, which would impact the Company’s strategic partners and in turn impact on demand for its products and services.

(x) Information Systems Risk

During fiscal year 2023, fiscal year 2024 and Fiscal 2025, the Company launched a new ERP system, which provides for a more robust and secure financial system of record, among other supply chain and operational data. Various IT general controls are now centralized currently in the midst of stabilizing a new ERP system, which replaces its previous financial system. There can be no assurance that the ERP system will provide the information and benefits expected by management.

The stabilization of the ERP system requires an investment of significant personnel and financial resources, including substantial expenditures for outside consultants, cloud computing and software costs, in addition to other expenses in connection with the transformation of the Company's organizational structure and financial and operating processes. The stabilization of the new ERP system may result in delays, increased costs and other difficulties, including potential design defects, miscalculations, testing requirements, and the diversion of management’s attention from day-to-day business operations. If it is unable to stabilize the new ERP system as planned, the effectiveness of the internal control over financial reporting could be adversely affected, the ability to assess those controls adequately and to disseminate its financial documents could be delayed, the Company’s operations could be affected and the Company’s financial condition, results of operations and cash flows could be negatively impacted.

15 Notably, a key tax implication of the Final Order is that state-licensed medical cannabis operators will no longer be subject to the deduction disallowance imposed by Section 280E of the Internal Revenue Code, which only applies to businesses dealing in schedule I or II controlled substances. The U.S. Department of the Treasury and Internal Revenue Service have announced they plan to issue guidance addressing the federal tax consequences. See U.S. Department of the Treasury, Treasury, IRS Announce Process for Tax Guidance Following DOJ Final Order on Medical Marijuana Rescheduling (April 23, 2026), https://home.treasury.gov/news/press-releases/sb0471.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    23

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain information herein contains or incorporates comments that constitute forward-looking information within the meaning of applicable securities legislation (“forward-looking information”). Forward-looking information, in general, can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “could”, “would”, “might”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “continue”, “budget”, “schedule” or “forecast” or similar expressions suggesting future outcomes or events. They include, but are not limited to, statements with respect to expectations, forecasts or other characterizations of future events or circumstances, and the Company’s objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to the Company’s plans and objectives, or estimates or predictions of actions of customers, suppliers, partners, distributors, competitors or regulatory authorities; and statements regarding the Company’s future economic performance. These statements are not historical facts but instead represent management beliefs regarding future events, many of which by their nature are inherently uncertain and beyond management control. Forward-looking information in this MD&A is based on the Company’s current expectations about future events.

Certain forward-looking information in this MD&A includes, but is not limited to the following:

•Expectations regarding production capacity, including seed-based cultivation, capability of the beverage manufacturing line, facility size, THC content, costs and yields;

•Expectations regarding the prospects of the Company’s collaboration and investment transaction with BAT;

•Expectations regarding the prospects for the Company’s primary operating subsidiary, Organigram Inc.;

•Expectations around demand for and distribution cannabis and related products, future opportunities and sales, including the relative mix of medical versus recreational cannabis products, the relative mix of products within the recreational category;

•Changes in legislation related to permitted cannabis types, forms, and potency, and legislation of additional cannabis types and forms for adult use recreational cannabis in Canada, including regulations relating thereto, the timing and the implementation thereof, and our future product forms;

•Expectations around branded cannabis products with respect to timing, launch, product attributes, composition and consumer demand;

•Expectations around the revenue growth from innovative products, particularly the commercialization of its new FASTTM nanoemulsion technology;

•The scope of protection the Company is able to establish and maintain, if any, for its intellectual property ("IP") rights;

•Strategic investments and capital expenditures, and expected related benefits;

•Expectations regarding the performance and integration of Sanity Group, the focus on growing margin accretive international sales, and the international revenue growth;

•Expectations regarding the Company's investments in OBX and Phylos;

•Expectations regarding the Company's M&A activities;

•Expectations regarding EU-GMP certification, including successful completion of the audit and follow-on correspondence with the regulator and timing for the issuance of the certification, if successful;

•The general continuance of current, or where applicable, assumed industry conditions;

•Changes in laws, regulations, guidelines, and policies, and the interpretation thereof, including those relating to the recreational and/or medical cannabis markets domestically and internationally, minor cannabinoids and environmental programs;

•The price of cannabis and derivative cannabis products;

•The impact of the Company’s cash flow and financial performance on third parties, including its supply partners;

•Fluctuations in the price of Common Shares and the market for Common Shares;

•The treatment of the Company's business under international regulatory regimes and impacts on changes thereto on the Company's international sales;

•The Company’s growth strategy, targets for future growth and forecasts of the results of such growth;

•Expectations concerning access to capital and liquidity, and the Company’s ability to access the public markets from time to time to fund operational activities and growth;

•Expectations concerning the Company's financial position, future liquidity and other financial results;

•The ability of the Company to generate cash flow from operations and from financing activities;

•The competitive conditions of the industry, including the Company’s ability to maintain or grow its market share;

•Expectations regarding the Company's ability to generate cost savings from operational effectiveness and automation initiatives;

•Expectations regarding capital expenditures and timing thereof; and

•Expectations concerning the Company's performance during the Fiscal 2026, including with respect to revenue, Adjusted Gross Margin, selling, general and administrative expenses, Adjusted EBITDA free cash flow, and cash from operations before working capital changes.

Forward-looking information is provided for the purposes of assisting the reader in understanding the Company and its business, operations, risks, financial performance, financial position and cash flows as at and for the periods ended on certain dates, and to present information about management’s current expectations and plans relating to the future, and the reader is cautioned that

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    24

such statements may not be appropriate for other purposes. In addition, this MD&A may contain forward-looking information attributed to third party industry sources. Undue reliance should not be placed on forward-looking information, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Forward-looking information does not guarantee future performance and involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. By its nature, forward-looking information involves numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the expectations, predictions, forecasts, projections and conclusions will not occur or prove accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These and other factors may cause actual results or events to differ materially from those anticipated in the forward-looking information.

Factors that could cause actual results to differ materially from those set forth in forward-looking information include, but are not limited to: financial risks; cyber security risks; dependence on senior management and other key personnel, the Board, consultants and advisors; availability and sufficiency of insurance including continued availability and sufficiency of director and officer and other forms of insurance; the Company and its subsidiaries being able to, where applicable, cultivate cannabis pursuant to applicable law and on the currently anticipated timelines and in anticipated volumes; industry competition; global events, including heightened economic and industry uncertainty as a result of any pandemic or epidemic and governmental action in respect thereto, including with respect to impacts on production, operations, disclosure controls and procedures or internal control over financial reporting, and supply chain and distribution disruptions; facility and technological risks; changes to government laws, regulations or policy, including the amendment of the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, environmental or tax, or the enforcement thereof; agricultural risks; ability to maintain any required licenses or certifications; supply risks; product risks; construction delays or postponements; packaging and shipping logistics; inflationary risk, expected number of medical and recreational cannabis users in Canada and internationally; continuation of shipments to existing and prospective international jurisdictions and customers; potential time frame for the implementation of legislation to legalize cannabis internationally; the Company’s, its subsidiaries' and its investees’ ability to, where applicable, obtain and/or maintain their status as LP or other applicable licensees; risk factors affecting its investees; availability of any required financing on commercially acceptable terms or at all; the potential size of the regulated recreational cannabis market in Canada; demand for and changes in the Company’s cannabis and related products, including the Company’s derivative products, and the sufficiency of the retail networks to supply such demand; ability to enter and participate in international market opportunities; general economic, financial market, regulatory, industry and political conditions affecting the Company; the ability of the Company to compete in the cannabis industry and changes in the competitive landscape; a material decline in cannabis prices; the Company’s ability to manage anticipated and unanticipated costs; the Company’s ability to implement and maintain effective internal control over financial reporting and disclosure controls and procedures; risks relating to potential failure of the Company's IT system; ongoing expansions to the Company's ERP system; continuing to meet listing standards for the TSX and the NASDAQ; risks relating to the Company's IP; liquidity risk; concentration risk; and other risks and factors described from time to time in the documents filed by the Company with securities regulators in Canada and the United States. Material factors and assumptions used in establishing forward-looking information include that production activities will proceed as planned, and demand for cannabis and related products will change in the manner expected by management. All forward-looking information is provided as of the date of this MD&A.

Certain forward-looking information included herein may also constitute a "financial outlook" within the meaning of applicable securities legislation. Financial outlook involves statements about the Company's prospective financial performance and financial position that are based on and subject to the assumptions about future economic conditions and courses of action described above as well as management's expectations regarding a strong innovation pipeline, increasing international sales, high cannabis quality and higher potency, commercialization of FAST nano-emulsion technology in ingestible formats, and receipt of the EU-GMP certification. Such assumptions are based on management's assessment of the relevant information currently available and any financial outlook included herein is provided for the purpose of helping readers understand management's current expectations and plans for the future as of the date hereof. The actual results of the Company's operations may vary from the amounts set forth in any financial outlook and such variances may be material. Readers are cautioned that reliance on any financial outlook may not be appropriate for other purposes, or in other circumstances and that the risk factors described above and other factors may cause actual results to differ materially from any financial outlook.

The Company does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required by law.

ADDITIONAL INFORMATION ABOUT THE ASSUMPTIONS, RISKS AND UNCERTAINTIES OF THE COMPANY’S BUSINESS AND MATERIAL FACTORS OR ASSUMPTIONS ON WHICH INFORMATION CONTAINED IN FORWARD-LOOKING INFORMATION IS BASED IS PROVIDED IN THE COMPANY’S DISCLOSURE MATERIALS, INCLUDING IN THIS MD&A UNDER “RISK FACTORS” AND THE COMPANY’S CURRENT AIF UNDER “RISK FACTORS”, FILED WITH THE SECURITIES REGULATORY AUTHORITIES IN CANADA AND AVAILABLE UNDER THE COMPANY’S ISSUER PROFILE ON SEDAR+ AT WWW.SEDARPLUS.CA, AND FILED WITH OR FURNISHED TO THE SEC AND AVAILABLE ON EDGAR AT WWW.SEC.GOV. ALL FORWARD-LOOKING INFORMATION IN THIS MD&A IS QUALIFIED BY THESE CAUTIONARY STATEMENTS.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    25

CAUTIONARY STATEMENT REGARDING CERTAIN NON-IFRS MEASURES

This MD&A contains certain financial and operational performance measures that are not recognized or defined under IFRS (i.e. non-IFRS measures). As there are no standardized methods of calculating these non-IFRS measures, the Company's approaches may differ from those used by others and this data may not be comparable to similar data presented by other LPs and cannabis companies. For an explanation of these measures related to comparable financial information presented in the Financial Statements prepared in accordance with IFRS, refer to the discussion below.

The Company believes that these non-IFRS measures are useful indicators of operating performance and are specifically used by management to assess the financial and operating performance of the Company. These non-IFRS measures include, but are not limited to, the following:

•Adjusted gross margin is calculated by subtracting cost of sales, before the effects of: (i) unrealized gain on changes in fair value of biological assets; (ii) realized fair value on inventories sold and other inventory charges; (iii) realized fair value on inventories sold from acquisitions; (iv) provisions and impairment of inventories and biological assets; and (v) provisions to net realizable value. Adjusted gross margin percentage is calculated by dividing adjusted gross margin by net revenue. Adjusted gross margin is reconciled to the most directly comparable IFRS financial measure in the "Financial Results and Review of Operations" section of this MD&A.

Management believes that these measures provide useful information to assess the profitability of our operations as they represent the normalized gross margin generated from operations and exclude the effects of non-cash fair value adjustments on inventories and biological assets, which are required by IFRS. The most directly comparable measure to adjusted gross margin calculated in accordance with IFRS is gross margin before fair value adjustments.

•Adjusted EBITDA is calculated as net income (loss) excluding: financing costs, net of investment income; income tax expense (recovery); depreciation, amortization, impairment, normalization of depreciation add-back due to changes in depreciable assets resulting from impairment charges, (gain) loss on disposal of property, plant and equipment (per the consolidated statement of cash flows); share-based compensation (per the consolidated statement of cash flows); share of loss (gain) from investments in associates including impairment loss; change in fair value of contingent consideration; change in fair value of derivative liabilities, other financial assets and preferred shares; expenditures incurred in connection with research and development activities (net of depreciation); unrealized gain on changes in fair value of biological assets; realized fair value on inventories sold and other inventory charges; provisions and net realizable value adjustments related to inventory and biological assets; government subsidies, insurance recoveries and other non-operating expenses (income); legal provisions (recoveries); ERP implementation costs; transaction costs; share issuance costs; and provision for Canndoc expected credit losses. Adjusted EBITDA is reconciled to the most directly comparable IFRS financial measure in the "Financial Results and Review of Operations" section of this MD&A.

During the second quarter of Fiscal 2024, management changed the calculation of adjusted EBITDA and has conformed prior quarters accordingly to include provision for expected credit losses.

Adjusted EBITDA is intended to provide a proxy for the Company’s operating cash flow and derives expectations of future financial performance for the Company, and excludes adjustments that are not reflective of current operating results. The most directly comparable measure to adjusted EBITDA calculated in accordance with IFRS is net income (loss).

•Free cash flow provided by (used in) operating activities is calculated as net cash provided by or used in operating activities less the purchase of property, plant and equipment. Free cash flow is reconciled to the most directly comparable IFRS financial measure in the "Balance Sheet, Liquidity and Capital Resources" section of this MD&A.

Free cash flow is a useful indicator of the Company's capacity to fund operations from internally generated cash flows, without the need for additional borrowings or use of existing cash reserves under normal operating conditions. The most directly comparable measure to free cash flow calculated in accordance with IFRS is net cash and restricted cash provided by (used in) operating activities.

Non-IFRS measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company’s operating results, underlying performance and prospects in a manner similar to the Company’s management. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025    26

TABLE OF CONTENTS
Condensed Consolidated Interim Statements of Financial Position									1
Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) Income									2
Condensed Consolidated Interim Statements of Changes in Equity									3
Condensed Consolidated Interim Statements of Cash Flows									4
Notes to the Condensed Consolidated Interim Financial Statements			5			–			17

ORGANIGRAM GLOBAL INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

As at March 31, 2026 and September 30, 2025

(Unaudited - expressed in CDN $000’s except share and per share amounts)

			MARCH 31, 2026						SEPTEMBER 30, 2025
ASSETS
Current assets
Cash			$	4,292					$	28,200
Short-term investments			811						826
Restricted cash (Note 4)			49,651						55,394
Accounts and other receivables (Note 5)			53,388						64,859
Biological assets (Note 6)			17,230						17,931
Inventories (Note 7)			117,928						106,023
Prepaid expenses and deposits			6,786						11,664
			250,086						284,897
Property, plant and equipment (Note 8)			120,838						122,977
Intangible assets (Note 9)			39,218						48,511
Goodwill			52,524						52,524
Deferred charges and deposits			1,515						3,754
Other financial assets (Note 10)			57,131						49,548
			$	521,312					$	562,211
LIABILITIES
Current liabilities
Accounts payable and accrued liabilities			$	73,139					$	89,247
Derivative liabilities (Note 11)			14,139						28,832
Other liabilities (Note 12)			1,467						8,080
			88,745						126,159
Derivative liabilities (Note 11)			—						5,506
Preferred shares (Note 13)			53,514						68,653
Other long-term liabilities (Note 12)			7,241						12,763
			149,500						213,081
SHAREHOLDERS' EQUITY
Share capital (Note 14)			924,185						919,908
Equity reserves			36,825						37,346
Accumulated other comprehensive income			481						603
Accumulated deficit			(589,679)						(608,727)
			371,812						349,130
			$	521,312					$	562,211

Subsequent events (Note 22)

On behalf of the Board:

/s/James Yamanaka, Director

/s/Peter Amirault, Director

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    1

ORGANIGRAM GLOBAL INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME

For the three and six months ended March 31, 2026 and 2025

(Unaudited - expressed in CDN $000’s except share and per share amounts)

			THREE MONTHS ENDED												SIX MONTHS ENDED
			MARCH 31, 2026						MARCH 31, 2025						MARCH 31, 2026						MARCH 31, 2025
REVENUE
Gross revenue (Note 18)			$	93,250					$	102,763					$	190,548					$	169,569
Excise taxes			(33,456)						(37,163)						(67,216)						(61,239)
Net revenue			59,794						65,600						123,332						108,330
Cost of sales			44,800						45,813						84,821						74,428
Gross margin before fair value adjustments			14,994						19,787						38,511						33,902
Realized fair value on inventories sold and other inventory charges (Note 7)			(21,834)						(14,192)						(38,745)						(27,258)
Unrealized gain on changes in fair value of biological assets (Note 6)			23,247						12,823						39,956						25,588
Gross margin			16,407						18,418						39,722						32,232
OPERATING EXPENSES
General and administrative (Note 19)			14,935						14,967						29,885						26,200
Sales and marketing			8,674						7,523						17,665						13,327
Research and development			2,025						2,662						4,109						5,031
Share-based compensation			566						849						1,274						2,058
Impairment of intangible assets (Note 9)			5,800						—						5,800						—
Total operating expenses			32,000						26,001						58,733						46,616
LOSS FROM OPERATIONS			(15,593)						(7,583)						(19,011)						(14,384)
Investment income, net of financing costs			(312)						(179)						(405)						(1,004)
Acquisition and transaction costs			4,356						974						5,962						5,478
Change in fair value of contingent consideration			(4,810)						(3,899)						(6,619)						(3,899)
Change in fair value of derivative liabilities, preferred shares and other financial assets (Note 17)			(14,524)						(47,155)						(38,916)						(32,660)
Share issuance costs allocated to derivative liabilities			—						170						—						170
Other non-operating expense, net			618						156						1,919						(1,862)
(Loss) income before tax			(921)						42,350						19,048						19,393
Income tax recovery
Deferred, net			—						(106)						—						(106)
NET (LOSS) INCOME			(921)						42,456						19,048						19,499
OTHER COMPREHENSIVE (LOSS) INCOME
Change in fair value of investments at fair value through other comprehensive (loss) income (Note 10)			$	297					(438)						(122)						(198)
COMPREHENSIVE (LOSS) INCOME			$	(624)					$	42,018					$	18,926					$	19,301
Net (loss) earnings per common share, basic			$	(0.007)					$	0.329					$	0.141					$	0.161
Net (loss) earnings per common share, diluted			$	(0.007)					$	0.318					$	0.139					$	0.155

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    2

ORGANIGRAM GLOBAL INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

For the six months ended March 31, 2026 and March 31, 2025

(Unaudited - expressed in CDN $000’s except share and per share amounts)

			NUMBER OF SHARES						SHARE CAPITAL						EQUITY RESERVES						ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)						ACCUMULATED DEFICIT						SHAREHOLDERS' EQUITY
Balance - October 1, 2024			108,585,492						$	852,891					$	37,129					$	(63)					$	(583,968)					$	305,989
Shares issued related to business combination, net of issue costs of $71			17,233,950						39,050						—						—						—						39,050
Private placement			7,562,447						23,963						—						—						—						23,963
Share-based compensation			—						—						2,263						—						—						2,263
Exercise of restricted share units			452,273						1,363						(1,363)						—						—						—
Exercise of performance share units			1,801						15						(15)						—						—						—
Net income			—						—						—												19,499						19,499
Other comprehensive loss			—						—						—						(198)						—						(198)
Balance - March 31, 2025			133,835,963						$	917,282					$	38,014					$	(261)					$	(564,469)					$	390,566
Balance - October 1, 2025			134,461,029						$	919,908					$	37,346					$	603					$	(608,727)					$	349,130
Shares issued to former shareholders of CPL, net of issue costs (Note 14 (i) and 20)			1,195,397						2,252						—						—						—						2,252
Share-based compensation (Note 14)			—						—						1,498						—						—						1,498
Exercise of stock options (Note 14)			3,350						11						(5)						—						—						6
Exercise of restricted share units (Note 14)			720,429						1,576						(1,576)						—						—						—
Exercise of performance share units (Note 14)			88,485						438						(438)						—						—						—
Net income			—						—						—						—						19,048						19,048
Other comprehensive loss			—						—						—						(122)						—						(122)
Balance - March 31, 2026			136,468,690						$	924,185					$	36,825					$	481					$	(589,679)					$	371,812

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    3

ORGANIGRAM GLOBAL INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

For the six months ended March 31, 2026 and 2025

(Unaudited - expressed in CDN $000’s except share and per share amounts)

									SIX MONTHS ENDED
															MARCH 31, 2026						MARCH 31, 2025
CASH PROVIDED BY (USED IN)
OPERATING ACTIVITIES
Net income															$	19,048					$	19,499
Items not affecting operating cash:
Share-based compensation (Note 14)															1,498						2,263
Depreciation and amortization															10,013						8,226
Impairment of intangible assets (Note 9)															5,800						—
Realized fair value on inventories sold and other inventory charges (Note 7)															38,745						27,258
Unrealized gain on changes in fair value of biological assets (Note 6)															(39,956)						(25,588)
Investment income, net of financing costs															(405)						(1,004)
Change in fair value of contingent consideration															(6,619)						(3,899)
Provisions and net realizable value adjustments related to inventory (Note 7)															3,785						—
Bad debts and provision for expected credit losses															827						—
Change in fair value of derivative liabilities, preferred shares and other financial assets (Note 17)															(38,916)						(32,660)
Unrealized foreign exchange loss (gain)															222						(2,054)
Share issuance costs allocated to derivative liabilities															—						$	170
Income tax recovery															—						(106)
Cash and restricted cash used in operating activities before working capital changes															(5,958)						(7,895)
Changes in non-cash working capital:
Net change in accounts and other receivables, biological assets, inventories, prepaid expenses and deposits															1,829						2,117
Net change in accounts payable and accrued liabilities, provisions and other liabilities															(18,644)						(14,987)
Net cash and restricted cash used in operating activities															(22,773)						(20,765)
FINANCING ACTIVITIES
Payment of share issue costs (Note 14)															(51)						—
Private placement, net of share issue costs															—						41,181
Payment of lease liabilities, net of sublease receipts															(831)						(693)
Payment of long-term debt															(25)						(30)
Stock options exercised															6						—
Net cash (used in) provided by financing activities															(901)						40,458
INVESTING ACTIVITIES
Purchase of short-term investments															(800)						(846)
Proceeds from short-term investments															820						836
Acquisition of subsidiary, net of cash acquired															—						(64,873)
Investment income															702						1,217
Other financial assets (Note 10)															(4,127)						—
Purchase of property, plant and equipment (Note 8)															(2,327)						(8,134)
Purchase of intangible assets															(23)						(52)
Net cash used in investing activities															(5,755)						(71,852)
Effect of foreign exchange on cash															(222)						2,054
DECREASE IN CASH AND RESTRICTED CASH															(29,651)						(50,105)
CASH AND RESTRICTED CASH
Beginning of period															83,594						132,605
End of period															$	53,943					$	82,500
Less: restricted cash															(49,651)						(69,319)
Cash as presented on the statement of financial position															$	4,292					13,181

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    4

ORGANIGRAM GLOBAL INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three and six months ended March 31, 2026 and March 31, 2025

(Unaudited - expressed in CDN $000’s except share and per share amounts)

1.    NATURE OF OPERATIONS

Organigram Global Inc. (formerly known as "Organigram Holdings Inc.") (the “Company”) is a publicly listed corporation with its common shares (the “Common Shares”) trading on the Toronto Stock Exchange (“TSX”) and on the Nasdaq Global Select Market (“NASDAQ”) under the symbol “OGI”. The head office of the Company is 1400-145 King Street West, Toronto, Ontario, Canada, M5H 1J8 and the registered office is 35 English Drive, Moncton, New Brunswick, Canada, E1E 3X3.

On March 24, 2025, the shareholders of the Company at the annual and special meeting of shareholders approved an amendment to the articles of the Company to change the name of the Company to “Organigram Global Inc". On March 31, 2025, the Company obtained all regulatory approvals for the change of name of the Company.

The Company’s wholly-owned subsidiaries are: (i) Organigram Inc., a licensed producer (“LP” or “Licensed Producer”) of cannabis and cannabis-derived products in Canada regulated by Health Canada under the Cannabis Act (Canada) and the Cannabis Regulations (Canada); (ii) 10870277 Canada Inc., a special purpose holding company for the Company; and (iii) Organigram USA Inc. (formerly known as Collective Project USA Limited) ("OGI USA"), a wholly-owned subsidiary of Organigram Inc. The Company was incorporated under the Business Corporations Act (British Columbia) on July 5, 2010, and continued under the Canada Business Corporations Act (“CBCA”) on April 6, 2016. Organigram Inc. was incorporated under the Business Corporations Act (New Brunswick) on March 1, 2013. 10870277 Canada Inc. was incorporated under the CBCA on July 4, 2018. OGI USA was incorporated under the General Corporation Law of the State of Delaware on April 12, 2019.

On October 1, 2023, Organigram Inc. amalgamated with the Company's then wholly-owned subsidiaries, The Edibles and Infusions Corporation ("EIC") and Laurentian Organic Inc. ("Laurentian"), and continued as a single corporation under the name "Organigram Inc.", a 100% owned subsidiary of the Company. EIC was incorporated under the Business Corporations Act (Ontario) on September 20, 2018. Laurentian was incorporated under the CBCA on March 18, 2019.

On April 1, 2025, Organigram Inc. amalgamated with the Company's then wholly-owned subsidiary, Motif Labs Ltd. ("Motif") and continued as a single corporation under the name "Organigram Inc.", a 100% owned subsidiary of the Company. Motif was incorporated under the Business Corporations Act (Ontario) on December 18, 2017.

On October 1, 2025, Organigram Inc. amalgamated with the Company's then wholly-owned subsidiary, Collective Project Limited (“CPL”) and continued as a single corporation under the name "Organigram Inc.", a 100% owned subsidiary of the Company. CPL was incorporated under the CBCA on October 23, 2013.

2.     BASIS OF PREPARATION

i.Statement of compliance

These unaudited condensed consolidated interim financial statements ("interim financial statements") have been prepared in accordance with International Accounting Standard 34 (“IAS 34”) - Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The interim financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the years ended September 30, 2025 and 2024 (“Annual Consolidated Financial Statements”), which have been prepared in accordance with International Financial Reporting Standards as issued by the IASB ("IFRS Accounting Standards").

These interim financial statements were approved and authorized for issue by the Board of Directors of the Company on May 7, 2026.

ii.Basis of measurement

These interim financial statements have been prepared on a historical cost basis except for biological assets, share-based compensation, contingent share consideration, short-term investments, preferred shares, other financial assets and derivative liabilities, which are measured at fair value.

Historical cost is the fair value of the consideration given in exchange for goods and services, which is generally based upon the fair value of the consideration given in exchange for assets at the time of the transaction.

iii.Basis of consolidation

These interim financial statements include the accounts of the Company and its subsidiaries on a consolidated basis after elimination of intercompany transactions and balances. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement and has the ability to affect those returns through its power to direct the relevant activities of the subsidiaries. The results of subsidiaries acquired during the year are consolidated from the date of acquisition.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    5

Associates are all entities over which the Company has significant influence but not control or joint control. Investments in associates are accounted for using the equity method after initial recognition at cost. Joint operations are arrangements in which the Company has joint control. The Company includes its proportionate share of the assets acquired and expenses incurred of the joint operation.

iv.Foreign currency translation

Functional and presentation currency

These interim financial statements are presented in Canadian dollars, which is the functional currency of the Company and its subsidiaries, except for one subsidiary (OGI USA) and an associate (Alpha-Cannabis Pharma GmbH), for which the functional currencies have been determined to be United States dollars and Euros, respectively.

3.     MATERIAL ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim financial statements are consistent with those followed in the preparation of the Company’s Annual Consolidated Financial Statements, except for the adoption of the following new standards and amendments.

New and amended accounting standards

Amendment to IAS 21: Lack of Exchangeability
In August 2023, the IASB amended IAS 21 to clarify when a currency is exchangeable into another currency and how a company estimates a spot rate when a currency lacks exchangeability. The amendments are effective for annual reporting periods beginning on or after January 1, 2025. The Company’s international transactions are limited to a few countries, such as the United States, the United Kingdom, Australia and Germany. These countries all have active markets for their currencies and therefore, there is no risk of a lack of exchangeability for these currencies.

These amendments do not have any material impact on the Company’s consolidated financial statements.

Critical accounting estimates and judgments

The preparation of the Company’s financial statements requires management to make estimates, assumptions and judgments that affect the application of accounting policies, and the reported amounts of assets, liabilities, revenues and expenses. Significant estimates and judgments used in preparation of the interim financial statements are described in the Company’s Annual Consolidated Financial Statements.

4.     RESTRICTED CASH

As at March 31, 2026, the Company held restricted cash balances of $49,651 (September 30, 2025 - $55,394). These balances represent the subscription agreement dated November 5, 2023, with BT DE Investments Inc., a wholly-owned subsidiary of British American Tobacco p.l.c ("BAT"), and are subject to contractual restrictions that limit their use for general corporate purposes. Accordingly, these amounts are presented separately in the consolidated statements of financial position and excluded from cash and cash equivalents in the consolidated statements of cash flows.

As of March 31, 2026, the Company had access to $10 million (March 31, 2025 - $nil) of previously restricted funds pursuant to a temporary waiver granted by BAT. The waiver permits use of these funds for general purposes through November 8, 2026, after which the original restrictions are reinstated. The Company has classified these funds as unrestricted cash based on the terms and substance of the arrangement. As of March 31, 2026, the Company had drawn $6 million (March 31, 2025 - $nil) of these funds.

5.    ACCOUNTS AND OTHER RECEIVABLES

The Company’s accounts and other receivables include the following balances as at March 31, 2026 and September 30, 2025:

			MARCH 31, 2026						SEPTEMBER 30, 2025
Gross trade receivables			$	57,914					$	69,288
Less: reserves for product returns and price adjustments			(497)						(734)
Less: expected credit losses			(5,796)						(4,969)
Trade receivables			51,621						63,585
Receivable from related party			971						701
Current portion of net investment in subleases			12						12
Other receivables			784						561
			$	53,388					$	64,859

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    6

6.     BIOLOGICAL ASSETS

The Company measures biological assets, which consist of cannabis plants, at fair value less costs to sell up to the point of harvest, which then becomes the basis for the cost of finished goods inventories after harvest. Subsequent expenditures incurred on these finished goods inventories after harvest are capitalized based on IAS 2 - Inventories.

The changes in the carrying value of biological assets as at March 31, 2026 are as follows:

			CAPITALIZED COST						BIOLOGICAL ASSET FAIR VALUE ADJUSTMENT						AMOUNT
Balance, September 30, 2025			$	6,032					$	11,899					$	17,931
Unrealized gain on changes in fair value of biological assets			—						39,956						39,956
Production costs capitalized			23,705						—						23,705
Transfer to inventory upon harvest			(20,738)						(43,624)						(64,362)
Balance, March 31, 2026			$	8,999					$	8,231					$	17,230

The fair value less costs to sell of biological assets is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, then adjusts that amount for the average selling price per gram, and for any additional costs to be incurred, such as post-harvest costs. The following unobservable inputs, all of which are classified as level 3 within the fair value hierarchy (see Note 17), are used in determining the fair value of biological assets:

i.average selling price per gram – calculated as the weighted average current selling price of cannabis sold by the Company, adjusted for expectations about future pricing;

ii.expected average yield per plant – represents the number of grams of finished cannabis inventory which is expected to be obtained from each harvested cannabis plant currently under cultivation;

iii.wastage of plants based on their various stages of growth – represents the weighted average percentage of biological assets which are expected to fail to mature into cannabis plants that can be harvested;

iv.post-harvest costs – calculated as the cost per gram of harvested cannabis to complete the sale of cannabis plants post-harvest, consisting of the cost of direct and indirect materials and labour related to drying, labelling, and packaging; and

v.stage of completion in the cultivation process – calculated by taking the average number of weeks in production over a total average grow cycle of approximately 14 weeks.

The Company estimates the harvest yields for the cannabis on plants at various stages of growth, based on expected yield of mature plants based on its historical experience. As of March 31, 2026, it is expected that the Company’s biological assets will yield 36,435 kg (September 30, 2025 – 35,108 kg) of cannabis when eventually harvested. Changes in fair value less costs to sell of biological assets are recognized in the condensed consolidated interim statements of operations and comprehensive (loss) income.

7.     INVENTORIES

The Company’s inventories are comprised of the following balances as at March 31, 2026 and September 30, 2025:

			March 31, 2026
			CAPITALIZED COST						FAIR VALUE ADJUSTMENT						CARRYING VALUE
Plants in drying stage			$	799					$	1,193					$	1,992
Dry cannabis
Available for packaging			28,182						27,579						55,761
Packaged inventory			6,730						777						7,507
Flower and trim available for extraction			4,391						1,853						6,244
Concentrated extract			1,525						397						1,922
Formulated extracts
Available for packaging			1,601						996						2,597
Packaged inventory			23,062						2,396						25,458
Packaging and supplies			16,447						—						16,447
			$	82,737					$	35,191					$	117,928

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    7

			SEPTEMBER 30, 2025
			CAPITALIZED COST						FAIR VALUE ADJUSTMENT						CARRYING VALUE
Plants in drying stage			$	4,794					$	2,928					$	7,722
Dry cannabis
Available for packaging			14,266						17,265						31,531
Packaged inventory			4,088						2,884						6,972
Flower and trim available for extraction			2,336						1,237						3,573
Concentrated extract			4,711						1,499						6,210
Formulated extracts
Available for packaging			20,267						668						20,935
Packaged inventory			11,414						346						11,760
Packaging and supplies			17,320						—						17,320
			$	79,196					$	26,827					$	106,023

Flower and trim available for extraction are converted into concentrated extract, which can then be used for oil formulation (combining with a carrier oil) or other products such as edibles, hash and vaporizable products.

The amount of inventory expensed in cost of sales for the three and six months ended March 31, 2026 was $34,962 and $69,177 (March 31, 2025 – $38,852 and $63,016), respectively. The amount of inventory provisions and waste for the three and six months ended March 31, 2026 was $4,816 and $6,566 (March 31, 2025 – $1,764 and $2,924), respectively, which include, provisions for excess and unsaleable inventories of $3,420 and $3,485 (March 31, 2025 – $548 and $561), respectively, adjustments to net realizable value of $27 and $300 (March 31, 2025 – $nil and $151), respectively and processing and packaging waste of $1,369 and $2,781 (March 31, 2025 – $1,216 and $2,212), respectively, which is comprised of the production or purchase costs of these inventories. The remaining balance of cost of sales relates to freight and operational overheads.

The amount of realized fair value on inventories sold and other inventory charges for the three and six months ended March 31, 2026 was $21,834 and $38,745 (March 31, 2025 – $14,192 and $27,258), respectively, including realized fair value on inventories sold of $19,910 and $36,705 (March 31, 2025 – $13,725 and $26,244), respectively. Inventory provisions to recognize the realized fair value on waste and to adjust to net realizable value during the three and six months ended March 31, 2026 were $1,951 and $2,340 (March 31, 2025 – $467 and $1,165), respectively, consisting of $27 and $300 (March 31, 2025 – $nil and $151), respectively, recognized in cost of sales and $1,924 and $2,040 (March 31, 2025 – $467 and $1,014), respectively, recognized in fair value adjustments.

8.    PROPERTY, PLANT AND EQUIPMENT

			LAND						BUILDINGS												GROWING & PROCESSING EQUIPMENT						LEASEHOLD IMPROVEMENTS						OTHER						RIGHT-OF-USE ASSETS						TOTAL
Cost
Balance, September 30, 2025			$	4,705					$	164,007											$	186,310					$	11,152					$	17,782					$	9,503					$	393,459
Additions			—						381												3,799						178						—						—						4,358
Balance, March 31, 2026			$	4,705					$	164,388											$	190,109					$	11,330					$	17,782					$	9,503					$	397,817
Accumulated depreciation and impairment
Balance, September 30, 2025			$	(2,721)					$	(109,222)											$	(143,350)					$	(1,327)					$	(12,268)					$	(1,594)					$	(270,482)
Depreciation			—						(1,620)												(3,571)						(320)						(310)						(676)						(6,497)
Balance, March 31, 2026			$	(2,721)					$	(110,842)											$	(146,921)					$	(1,647)					$	(12,578)					$	(2,270)					$	(276,979)
Net book value
September 30, 2025			$	1,984					$	54,785											$	42,960					$	9,825					$	5,514					$	7,909					$	122,977
March 31, 2026			$	1,984					$	53,546											$	43,188					$	9,683					$	5,204					$	7,233					$	120,838

Included in deferred charges and deposits is $1,399 (September 30, 2025 – $3,540) paid to secure the acquisition of growing and processing equipment. The amounts will be recorded in property, plant and equipment as equipment is received.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    8

Reconciliation of property, plant, and equipment additions to the statements of cash flows

The following table reconciles additions of property, plant, and equipment per the above table to the purchases of property, plant, and equipment per the statements of cash flows:

			MARCH 31, 2026						MARCH 31, 2025
Total additions (including right-of-use lease assets)			$	4,358					$	29,616
Additions related to business combinations			—						(25,608)
Net change in deferred charges and deposits related to purchases of property, plant and equipment			(1,797)						5,954
Net change in accounts payable and accrued liabilities related to purchases of property, plant and equipment			(234)						(1,828)
Purchase of property, plant and equipment			$	2,327					$	8,134

9.    INTANGIBLE ASSETS

Cash generating unit ("CGU") Impairment

During the three and six months ended March 31, 2026, the Company identified indicators of impairment related to the CPL CGU primarily as a result of regulatory restrictions affecting hemp-derived products in the U.S. market. This regulatory development adversely impacted management’s expectations regarding future revenues, profitability and cash flows associated with the CGU.

Accordingly, the Company performed an impairment assessment in accordance with IAS 36, Impairment of Assets. The recoverable amount of the CPL CGU was determined using a value-in-use methodology based on cash flow projections derived from management-approved forecasts covering a period of approximately 4 years. The key assumptions used in the valuation included forecast revenues, expected operating margins, anticipated impacts of regulatory restrictions, a pre-tax discount rate of 15.5% and a long-term average annual forecast growth rate of 1.3% reflecting the risks specific to the CGU and industry conditions.

Based on the assessment performed, the recoverable amount of the CPL CGU was determined to be approximately $5,800 lower than its carrying amount as at March 31, 2026. Accordingly, the Company recognized an impairment loss of $5,800 during the period.

10. OTHER FINANCIAL ASSETS

The following table outlines changes in other financial assets. Note 17 provides additional details on the fair value calculation of each investment.

ENTITY						ASSET TYPE						BALANCE, SEPTEMBER 30, 2025						FUNDED						FAIR VALUE CHANGES						BALANCE, MARCH 31, 2026
Weekend Holdings Corp. ("WHC")						Preferred shares						$	6,107					$	—					$	(122)					$	5,985
Phylos Bioscience Inc. ("Phylos")						Secured convertible loan						$	12,459					$	4,127					$	(2,672)					$	13,914
Steady State LLC (d/b/a Open Book Extracts) ("OBX")						Convertible loan						$	3,462					$	—					$	204					$	3,666
Sanity Group GmbH ("Sanity Group")						Convertible loan						$	23,552					$	—					$	6,939					$	30,491
Sanity Group						Common shares						$	3,968					$	—					$	(893)					$	3,075
												$	49,548					$	4,127					$	3,456					$	57,131

Phylos Bioscience Inc.

In December 2025, the secured convertible loan agreement (the “Secured Convertible Loan Agreement”) entered into on May 25, 2023 was amended to provide for additional advances of up to US$3.0 million, increasing the total aggregate principal amount available under the agreement to US$10.0 million. The amendment also revised certain milestones, maturity, conversion and warrant terms, and introduced provisions for the suspension of interest accrual commencing on May 24, 2028. During the three and six months ended March 31, 2026, the Company advanced US$1,181 ($1,617) and US$3,000 ($4,127), respectively to Phylos in accordance with the amended Secured Convertible Loan Agreement.

11.    DERIVATIVE LIABILITIES

The following table outlines changes in derivative liabilities, which are measured at fair value with changes recognized in the condensed consolidated interim statements of operations and comprehensive (loss) income.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    9

			MARCH 31, 2026												SEPTEMBER 30, 2025
			CURRENT						LONG-TERM						CURRENT						LONG-TERM
Top-up Rights			$	12,357					$	—					$	28,821					$	—
Secured Convertible Loan Agreement			—						—						11						—
Warrants			1,782						—						—						5,506
			$	14,139					$	—					$	28,832					$	5,506

i.    Top-up Rights

As at March 31, 2026, the Company revalued the top-up rights (the "Top-up Rights") of BAT to an estimated fair value of $12,357 (September 30, 2025 – $28,821). The Company recorded a decrease in the estimated fair value change of the Top-up Rights for the three and six months ended March 31, 2026 of $4,307 and $16,464 (March 31, 2025 – $20,487 and $1,542).

The following inputs were used to estimate the fair value of the Top-up Rights at March 31, 2026 and September 30, 2025:

			MARCH 31, 2026
			STOCK OPTIONS						WARRANTS						PSUs						RSUs						TOP-UP OPTIONS
Average exercise price			$1.20 - $45.08						$3.65						$—						$—						$1.90 - $3.00
Risk free interest rate			2.33% - 2.93%						2.82%						2.92%						2.91%						2.70%
Expected future volatility of Common Shares			55.00% - 70.00%						60.00%						70.00%						70.00%						40.00%
Expected life (years)			0.31 - 3.12						2.01						3.00						2.89						0.04
Forfeiture rate			10%						—%						25%						5%						—%

			SEPTEMBER 30, 2025
			STOCK OPTIONS						WARRANTS						PSUs						RSUs						TOP-UP OPTIONS
Average exercise price			$1.20 - $45.08						$3.65						$—						$—						$1.20 - $2.23
Risk free interest rate			2.44% - 2.57%						2.50%						2.48%						2.46%						3.10%
Expected future volatility of Common Shares			60.00% - 70.00%						70.00%						70.00%						70.00%						40.00%
Expected life (years)			1.42 - 3.26						2.42						2.10						1.75						0.34
Forfeiture rate			10%						—%						25%						5%						—%

ii.    Warrants

During the three and six months ended March 31, 2026, no warrants were exercised. As at March 31, 2026, the Company revalued the derivative liability for warrants to an estimated fair value of $1,782 (September 30, 2025 – $5,506). The Company recorded a decrease in the estimated fair value of the derivative liabilities for the three and six months ended March 31, 2026 of $2,862 and $3,724 (March 31, 2025 – decrease of $2,398 and $5,746), respectively.

The following inputs were used to estimate the fair value of the warrants as at March 31, 2026:

			MARCH 31, 2026
Risk free interest rate			2.79		%
Life of Warrants (years)			2.01
Market price of Common Shares			$	1.85
Expected future volatility of Common Shares			72.20		%
Fair value per Warrant			$	0.40

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    10

12.    OTHER CURRENT AND LONG-TERM LIABILITIES

The carrying value of other current and long-term liabilities as at March 31, 2026 and September 30, 2025 consists of:

			MARCH 31, 2026												SEPTEMBER 30, 2025
			CURRENT						LONG-TERM						CURRENT						LONG-TERM
Lease liabilities			$	957					$	7,241					$	979					$	7,748
Contingent consideration (Note 20)			510						$	—					6,719						5,015
Deferred consideration			—						$	—					357						—
Long-term debt			—						—						25						—
			$	1,467					$	7,241					$	8,080					$	12,763

i.    Contingent consideration

As at March 31, 2026, the fair value of the contingent consideration was $510. During the three and six months ended March 31, 2026, the Company recognized a fair value gain of $4,810 and $3,701 in the condensed consolidated interim statements of operations and comprehensive (loss) income. The decrease of the contingent consideration liabilities reflects updated expectations related to achievement of the CPL earnout payment.

13.    PREFERRED SHARES

As at March 31, 2026, the Company revalued the Preferred Shares to an estimated fair value of $53,514 (September 30, 2025 – $68,653). For the three and six months ended March 31, 2026, the Company recognized a fair value gain of $1,502 and $15,139 (March 31, 2025 – $14,825 and $11,089), respectively in the condensed consolidated interim statements of operations and comprehensive (loss) income.

14.    SHARE CAPITAL

i.    Issuances of share capital

The CPL acquisition

During the six months ended March 31, 2026, the Company issued 1,195,397 Common Shares on CPL's achievement of the first earnout milestone set in the CPL share purchase agreement for share consideration of $2,303, less share issuance costs of $51 (Note 20).

Exercise of stock options

During the six months ended March 31, 2026, 3,350 (March 31, 2025 – nil) share options were exercised at an average exercise price of $1.90 (March 31, 2025 - $nil) for an increase of $11 (March 31, 2025 - $nil) to share capital and a decrease to equity reserves of $5 (March 31, 2025 - $nil).

Exercise of restricted share units ("RSUs")

During the six months ended March 31, 2026, 720,429 (March 31, 2025 – 452,273) RSUs were exercised for an increase of $1,576 (March 31, 2025 – $1,363) to share capital and a decrease to equity reserves of $1,576 (March 31, 2025 – $1,363).

Exercise of performance share units ("PSUs")

During the six months ended March 31, 2026, 88,485 (March 31, 2025 – 1,801) PSUs were exercised for an increase of $438 (March 31, 2025 – $15) to share capital and a decrease to equity reserves of $438 (March 31, 2025 - decrease of $15).

ii.    Share-based compensation

During the three and six months ended March 31, 2026, the Company recognized total share-based compensation charges, including those related to production employees which are charged to biological assets and inventory, of $728 and $1,498 (March 31, 2025 – $938 and $2,263), respectively.

Stock options

The following table summarizes changes in the Company’s outstanding stock options for the six months ended March 31, 2026:

			NUMBER						WEIGHTED AVERAGE EXERCISE PRICE
Balance - September 30, 2025			2,301,674						$	10.03
Exercised			(3,350)						1.90
Expired			(168,316)						7.95
Balance - March 31, 2026			2,130,008						$	10.20

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    11

For the three and six months ended March 31, 2026, share-based compensation charges, including related to production employees that are charged to biological assets and inventory, were $nil and $nil (March 31, 2025 – $10 and $23), respectively, related to the Company’s stock option plan.

Restricted share units

The following table summarizes the movement in the Company’s outstanding RSUs:

			NUMBER
Balance - September 30, 2025			2,996,794
Granted			1,144,083
Exercised			(720,429)
Cancelled / Forfeited			(242,412)
Balance - March 31, 2026			3,178,036

The estimated fair value of the equity settled RSUs granted during the six months ended March 31, 2026 was $2,426 (March 31, 2025 – $2,490), which was based on the Company’s share price at the grant date and will be recognized as an expense over the vesting period of the RSUs, which is over a period of three years for most grants.

For the three and six months ended March 31, 2026, $641 and $1,564 (March 31, 2025 – $770 and $1,841), respectively, has been recognized as share-based compensation expense.

Performance share units

The following table summarizes the movements in the Company’s outstanding PSUs:

			NUMBER
Balance - September 30, 2025			1,677,762
Granted			728,261
Exercised			(88,485)
Cancelled / Forfeited			(371,139)
Balance - March 31, 2026			1,946,399

The estimated fair value of the equity-settled PSUs granted during the six months ended March 31, 2026 was $1,066 (March 31, 2025 – $812), which was based on the Company’s share price at the grant date, adjusted for an estimate of the likelihood of forfeiture, and will be recognized as an expense over the vesting period of the PSUs, which is three years.

For the three and six months ended March 31, 2026, expense (recovery) of $87 and $(66) (March 31, 2025 – expense of $158 and $399), respectively, has been recognized as share-based compensation expense.

15.    RELATED PARTY TRANSACTIONS AND BALANCES

Key management personnel are those persons having the authority and responsibility for planning, directing, and controlling activities of the Company, directly or indirectly. The key management personnel of the Company are the members of the Company’s executive management team and Board of Directors. The transactions are conducted at arm's length and in the normal course of operations.

Management and Board Compensation

For the three and six months ended March 31, 2026 and March 31, 2025, the Company’s expenses included the following management and Board of Directors compensation:

			THREE MONTHS ENDED												SIX MONTHS ENDED
			MARCH 31, 2026						MARCH 31, 2025						MARCH 31, 2026						MARCH 31, 2025
Salaries and bonus			$	1,617					$	1,324					$	2,994					$	2,626
Share-based compensation			511						646						987						1,421
Total key management compensation			$	2,128					$	1,970					$	3,981					$	4,047

During the three and six months ended March 31, 2026, nil and 650,061 RSUs (March 31, 2025 – nil and 404,905), respectively were granted to key management personnel with an aggregate fair value of $nil and $1,586 (March 31, 2025 – $nil and $1,538), respectively. In addition, for the three and six months ended March 31, 2026, nil and 379,254 PSUs (March

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    12

31, 2025 – nil and 404,905), respectively, were issued to key management personnel with an aggregate fair value of $nil and $925 (March 31, 2025 – $nil and $457), respectively.

Significant Transactions with Associates and Joint Operations

The Company has transactions with related parties, as defined in IAS 24 Related Party Disclosures, all of which are undertaken in the normal course of business.

For the three and six months ended March 31, 2026, under the product development collaboration agreement between the Company and BAT dated March 10, 2021, BAT incurred $675 and $1,350 (March 31, 2025 – $824 and $1,242), respectively, of direct expenses and the Company incurred $1,080 and $2,307 (March 31, 2025 – $1,450 and $2,924), respectively, of direct expenses and capital expenditures of $nil and $nil (March 31, 2025 – $nil and $nil), respectively, related to the Center of Excellence. The Company recorded in the three and six months ended March 31, 2026, $877 and $1,828 (March 31, 2025 – $1,137 and $2,083), respectively of these expenditures within research and development expenses in the condensed consolidated interim statements of operations and comprehensive (loss) income. For the three and six months ended March 31, 2026, the Company recorded $nil and $nil (March 31, 2025 – $nil and $nil), respectively, of capital expenditures which are included in the condensed consolidated interim statements of financial position.

At March 31, 2026, there is a balance receivable from BAT of $971 (September 30, 2025 – $2,001).

In November 2023, the Company entered into a subscription agreement with BAT for a $124.6 million follow-on BAT investment, whereby BAT, agreed to subscribe for a total of 38,679,525 Common Shares and Preferred Shares (the "Shares") at a price of $3.2203 per Share, subject to the receipt of shareholder approval, certain regulatory approvals and other conditions. On February 28, 2025, the Company closed the third and final tranche of the follow-on BAT investment and issued 7,562,447 Common Shares and 5,330,728 Preferred Shares of the Company.

16.     CAPITAL MANAGEMENT

The Company's capital consists of derivative liabilities, preferred shares, share capital, equity reserves, accumulated other comprehensive loss, and accumulated deficit, which at March 31, 2026 is $439,465 (September 30, 2025 - $452,146). Equity reserves are comprised of any amounts recorded with respect to the recognition of share-based compensation expense (stock options, RSUs, or PSUs) and the fair value of warrants classified as equity. Accumulated other comprehensive loss is entirely comprised of fair value changes recorded on the Company's investment in WHC.

The Company manages its capital structure and adjusts it based on funds available to the Company, in order to fund its growth. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company’s management to sustain future development of the business.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative stage of the Company, is reasonable. There were no changes to the Company's approach to capital management during the period.

17.    FAIR VALUE OF FINANCIAL INSTRUMENTS AND FINANCIAL RISK FACTORS

i.Fair value of financial instruments

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The Company categorizes its fair value measurements according to a three-level hierarchy. The hierarchy prioritizes the inputs used by the Company’s valuation techniques. A level is assigned to each fair value measurement based on the lowest-level input significant to the fair value measurement in its entirety.

The three levels of the fair value hierarchy are described as follows:

•level 1 inputs are quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date;

•level 2 inputs, other than quoted prices included within level 1, that are observable for the asset or liability, either directly or indirectly; and

•level 3 inputs are unobservable inputs for the asset or liability.

The fair values of cash, short term investments, accounts and other receivables, accounts payable and accrued liabilities and restricted funds approximate their carrying amounts due to their short-term nature.

The fair value of the investment in WHC is primarily based on level 3 unobservable inputs and is determined using a market-based approach, based on revenue multiples for comparable companies.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    13

The fair value of the secured convertible loan advanced to Phylos under the Secured Convertible Loan Agreement, as amended, was determined using the Cox-Ross-Rubinstein binomial lattice option pricing model and has been classified as level 3 in the fair value hierarchy. The fair value of the secured convertible loan was based on certain assumptions, including likelihood, and timing of the federal legalization or decriminalization of cannabis in the United States. Similarly, the fair value of the commitment to fund an additional US $1 million was based on certain assumptions, including the probability of Phylos achieving required milestones.

The fair value of the convertible promissory note issued to OBX was determined using the binomial lattice model. The key assumptions used in the model are OBX stock price, dividend yield, expected future volatility of OBX stock, credit risk-adjusted discounting rate, risk-free rate, and probability and timing of certain qualified events. The credit risk-adjusted discounting rate and the expected equity volatility are based on unobservable inputs and are categorized as level 3 in the fair value hierarchy.

The fair value of the Top-up Rights is based on level 3 inputs utilized in a Monte Carlo pricing model to estimate the fair value of such Top-up Rights. The key assumptions used in the model are the expected future price of the Company’s Common Shares, the weighted average expected life of the instruments and the expected future volatility of Common Shares.

The fair value of the convertible note issued by Sanity Group to the Company and the Company's equity interest in the Sanity Group was determined using the current value method and is primarily based on Level 3 unobservable inputs. Under this method, it is assumed that Sanity Group would be sold as of March 31, 2026, with the resulting proceeds distributed in accordance with investors’ liquidation rights. The key input to the valuation is the estimated equity value of Sanity Group, derived from the fair value of the deemed purchase consideration and incorporating assumptions related to forecast revenues and expenses, volatility assumptions, and discount rate.

The fair value of derivative warrant liabilities is based on level 1 and 2 inputs utilized in a Black-Scholes option pricing model to estimate the fair value of such warrants. The key assumption used in the model is the expected future volatility in the price of the Company’s Common Shares. If the expected future volatility in the common share price of the Company increased by 10%, the estimated fair value of the derivative warrant liability and net loss would increase by $536 or if it decreased by 10%, the estimated fair value of the derivative warrant liability and net loss would decrease by $562.

The fair value of the additional contingent share consideration payable to Motif's former shareholders in connection with the Company's acquisition of Motif in December 2024 is primarily based on level 3 unobservable inputs in a Monte Carlo pricing model. The model simulates daily share price of the Company for twelve months and monitors when the share achieves a volume weighted average trading price, which would trigger the issuance of the contingent share consideration. The key assumptions used in the model are expected future price and the expected future volatility of the Company's Common Shares.

The fair value of the additional contingent consideration payable to CPL's former shareholders in connection with the Company's acquisition of CPL in March 2025 is primarily based on level 3 unobservable inputs in a Monte Carlo pricing model. The determination of the fair value of this liability is primarily driven by the Company’s expectations of CPL achieving its milestones. The key inputs used in the model are revenue, discount rate, revenue and asset volatility and risk free rate.

The fair value of Preferred Shares is based on level 1, level 2 and level 3 inputs and is determined based on market price and volatility of the Company's Common Shares, risk free rate and discount for lack of marketability.

During the period, there were no transfers of amounts between levels 1, 2 and 3.

For the three and six months ended March 31, 2026, and March 31, 2025, the Company recorded the following fair value changes related to its financial instruments:

			THREE MONTHS ENDED												SIX MONTHS ENDED
			MARCH 31, 2026						MARCH 31, 2025			0			MARCH 31, 2026			0			MARCH 31, 2025
Investment in Phylos			$	(216)					$	(1,048)		$	—		$	2,672		$	—		$	(3,519)
Investment in OBX			(137)						(67)			—			(204)			—			(355)
Investment in Sanity Group (convertible loan)			(6,239)						(1,678)			—			(6,939)			—			(2,829)
Investment in Sanity Group (common shares)			780						(386)			—			893			—			(339)
Top-up Rights			(4,307)						(20,487)			—			(16,464)			—			(1,542)
Commitment to fund third tranche of Phylos convertible loan			(41)						—			—			(11)			—			(304)
Commitment to issue Preferred Shares			—						(6,266)			—			—			—			(6,937)
Warrants			(2,862)						(2,398)			—			(3,724)			—			(5,746)
Preferred shares			(1,502)						(14,825)			—			(15,139)			—			(11,089)
			$	(14,524)					$	(47,155)		$	—		$	(38,916)		$	—		$	(32,660)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    14

Additionally, for the three and six months ended March 31, 2026, and March 31, 2025, the Company also fair valued its investment in WHC and recognized a decrease in fair value of $297 and $122 (March 31, 2025 – decrease of $438 and $198) in the consolidated statements of operations and comprehensive income (loss) within other comprehensive income (loss).

ii.Financial risk factors

The Company is exposed to various risks through its financial instruments, as follows:

(a) Credit risk arises from deposits with banks, short-term investments, outstanding trade and other receivables, restricted funds and other financial assets. For trade receivables, the Company does not hold any collateral as security but mitigates this risk by dealing only with what management believes to be financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance, except potentially from outstanding receivable from one of the international customers. For certain trade and other receivables, management also obtains insurance, guarantees or general security agreements, where applicable. The maximum exposure to credit risk of cash, restricted cash, short-term investments, accounts and other receivables and other financial assets on the statement of financial position at March 31, 2026 approximates $165,273 (September 30, 2025 – $198,827).

As of March 31, 2026 and September 30, 2025, the Company’s aging of trade receivables was as follows:

			MARCH 31, 2026						SEPTEMBER 30, 2025
0-90 days			$	45,573					$	56,442
More than 90 days			12,341						12,846
Gross trade receivables			$	57,914					$	69,288
Less: Expected credit losses and reserve for product returns and price adjustments			(6,293)						(5,703)
			$	51,621					$	63,585

(b) Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company manages its liquidity risk by reviewing its capital requirements and liquidity position on an ongoing basis. At March 31, 2026, the Company had $4,292 (September 30, 2025 – $28,200) of cash (unrestricted) and working capital of $161,341 (September 30, 2025 – $158,738).

Subsequent to March 31, 2026, the Company completed the acquisition of Sanity Group and related financing transactions, including a private placement and the establishment of senior secured credit facilities. These transactions are expected to strengthen the Company’s liquidity position and provide additional funding capacity to support ongoing operations and integration activities. If necessary, the Company may access additional liquidity through the capital markets, including both debt and equity financing.

The Company is obligated to the following contractual maturities relating to their undiscounted cash flows as at March 31, 2026:

			Carrying Amount			Contractual Cash Flows			Less than 1 year			1 to 3 years			3 to 5 years			More than 5 years
Accounts payable and accrued liabilities			73,139			73,139			73,139			—			—			—
Lease obligations			8,198			10,478			1,531			3,197			2,818			2,932
			$	81,337		$	83,617		$	74,670		$	3,197		$	2,818		$	2,932

The contractual maturities noted above are based on contractual due dates of the respective financial liabilities.

In connection with the Company’s facilities, the Company is contractually committed to approximately $930 of capital expenditures.

(c) Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk for the Company is comprised of interest rate risk. Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates relates primarily to the Company’s debt obligations with floating interest rates. The Company has determined that a 1% change in rates would not have a material impact on the interim financial statements.

18.    REVENUE

Net revenue for the Company is defined as gross revenue, which is net of any customer discounts, rebates, and sales returns and recoveries, less excise taxes.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    15

Gross revenue for the three and six months ended March 31, 2026 and March 31, 2025 is disaggregated as follows:

			THREE MONTHS ENDED												SIX MONTHS ENDED
			MARCH 31, 2026						MARCH 31, 2025						MARCH 31, 2026						MARCH 31, 2025
Recreational revenue (Canadian)			$	83,498					$	93,126					$	171,329					$	155,760
Wholesale to licensed producers (Canadian)			2,927						2,858						6,519						3,204
International wholesale			6,090						6,069						11,132						9,399
Direct to patient medical and medical wholesale revenue (Canadian)			652						710						1,410						1,206
Other revenue			83						—						158						—
Gross revenue			$	93,250					$	102,763					$	190,548					$	169,569
Excise taxes			(33,456)						(37,163)						(67,216)						(61,239)
Net revenue			$	59,794					$	65,600					$	123,332					$	108,330

Recreational revenue is primarily generated from sales to provincial government distributors and large retailers that sell cannabis through their respective distribution networks. International and domestic wholesale revenue consists of bulk shipments to other cannabis companies, including Licensed Producers, for further processing and resale to end customers.

During the three and six months ended March 31, 2026, the Company had four and four customers (March 31, 2025 – three and four customers), respectively, that individually represented more than 10% of the Company’s net revenue.

19.    GENERAL AND ADMINISTRATIVE EXPENSES BY NATURE

			THREE MONTHS ENDED												SIX MONTHS ENDED
			MARCH 31, 2026						MARCH 31, 2025						MARCH 31, 2026						MARCH 31, 2025
Office and general			$	5,829					$	4,586					$	10,489					$	8,027
Wages and benefits			4,783						6,278						9,790						11,266
Professional fees			1,803						1,480						4,481						2,956
Depreciation and amortization			2,167						2,204						4,382						3,261
Travel and accommodation			145						216						301						370
Utilities			208						203						442						320
Total general and administrative expenses			$	14,935					$	14,967					$	29,885					$	26,200

20.    ACQUISITION OF SUBSIDIARIES

i.Acquisition of CPL

During the three and six months ended March 31, 2026, the Company finalized the purchase price allocation for the acquisition of CPL, which had been accounted for on a provisional basis in prior periods. There were no material adjustments to the provisional amounts recognized at the acquisition date. Accordingly, the amounts recognized for identifiable assets acquired, liabilities assumed, and goodwill remain consistent with those disclosed in the Company’s annual consolidated financial statements for the year ended September 30, 2025.

The contingent consideration is measured at fair value at each reporting date. As at March 31, 2026, the fair value of the contingent consideration was $510. During the three and six months ended March 31, 2026, the Company recognized a fair value gain of $4,810 and $3,701 in the condensed consolidated interim statements of operations and comprehensive (loss) income. The decrease of the contingent consideration liabilities reflects updated expectations related to achievement of the CPL earnout payment. The total contingent consideration is included in the other current liabilities.

In February 2026, the Company settled the First Earnout of $4,605 through a combination of cash and the issuance of common shares.

21.     OPERATING SEGMENTS

An operating segment is a component of the Company for which discrete financial information is available and whose operating results are regularly reviewed by the Company's chief operating decision maker, to make decisions about resources to be allocated to the segment and assess its performance, and that engages in business activities from which it may earn revenue and incur expenses. The Company has one operating segment.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    16

22.    SUBSEQUENT EVENTS

In April 2026, subsequent to the reporting date, the Company completed the acquisition of Sanity Group pursuant to a share purchase agreement dated February 18, 2026. A wholly owned subsidiary of the Company acquired all of the issued and outstanding shares of Sanity Group not already owned by the Company for an upfront consideration of €107.3 million ($174.2 million), comprising €78.0 million ($126.8 million) in cash and €29.3 million ($47.4 million) in share consideration. In addition, Sanity shareholders are entitled to receive an additional contingent consideration of up to €113.8 million ($184.4 million) comprising €20 million ($32.4 million) in cash and €93.8 million ($152.0 million) in share consideration. The amount of contingent consideration is dependent on Sanity's post-acquisition net revenue and EBITDA performance.

In connection with the acquisition, the Company completed a private placement financing with BAT for gross proceeds of €40.3 million ($65.2 million) and entered into senior secured credit facilities of up to $60.0 million with ATB Financial. The credit facilities consist of a term loan, revolving credit facility, and operating line, maturing in April 2029. Of the total facility, $20.0 million was drawn under the term loan to fund the acquisition.

As a result of the acquisition, restricted cash was fully utilized in accordance with its designated purpose.

As the acquisition was completed after the reporting date, it has not been recognized in these interim condensed consolidated financial statements.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025    17

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, James Yamanaka, Chief Executive Officer of Organigram Global Inc., certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Organigram Global Inc. (the "issuer") for the interim period ended March 31, 2026.

2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer.

5. Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework: The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is the Internal Control - Integrated Framework (COSO Framework 2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ICFR - material weakness relating to design: The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period

(a) a description of the material weakness;

(b) the impact of the material weakness on the issuer's financial reporting and its ICFR; and

(c) the issuer's current plans, if any, or any actions already undertaken, for remediating the material weakness.

5.3 Limitation on scope of design: The issuer has described in its interim MD&A

(a)the fact that the issuer’s other certifying officer(s) and I have limited the scope of our design of DC&P and ICFR to exclude controls, policies and procedures of

(i)N/A

(ii)N/A

(iii)a business that the issuer acquired not more than 365 days before the last day covered by the period of the interim filings; and

(b)summary financial information about the proportionately consolidated entity, special purpose entity or business that the issuer acquired that has been proportionately consolidated or consolidated in the issuer’s financial statements.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2026 and ended on March 31, 2026 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: May 12, 2026

(signed) “James Yamanaka”

James Yamanaka

Chief Executive Officer

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, Greg Guyatt, Chief Financial Officer of Organigram Global Inc., certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Organigram Global Inc. (the "issuer") for the interim period ended March 31, 2026.

2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer.

5. Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework: The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is the Internal Control - Integrated Framework (COSO Framework 2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ICFR - material weakness relating to design: The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period

(a) a description of the material weakness;

(b) the impact of the material weakness on the issuer's financial reporting and its ICFR; and

(c) the issuer's current plans, if any, or any actions already undertaken, for remediating the material weakness.

5.3 Limitation on scope of design: The issuer has described in its interim MD&A

(a)the fact that the issuer’s other certifying officer(s) and I have limited the scope of our design of DC&P and ICFR to exclude controls, policies and procedures of

(i)N/A

(ii)N/A

(iii)a business that the issuer acquired not more than 365 days before the last day covered by the period of the interim filings; and

(b)summary financial information about the proportionately consolidated entity, special purpose entity or business that the issuer acquired that has been proportionately consolidated or consolidated in the issuer’s financial statements.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2026 and ended on March 31, 2026 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: May 12, 2026

(signed) “Greg Guyatt”

Greg Guyatt

Chief Financial Officer

Organigram Reports Second Quarter Fiscal 2026 Results

TORONTO, ON, May 12, 2026 - Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 (“Q2 Fiscal 2026” or "Q2").

Q2 FISCAL 2026 HIGHLIGHTS

•Gross Revenue: $93.3 million (-9% year-over-year).

•Net Revenue: $59.8 million (-9% year-over-year).

•International Revenue: $6.1 million (0% year-over-year).

•Adjusted EBITDA2: $0.9 million (-82% year-over-year).

•#1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #5 in beverages1.

•Sanity Group GmbH ("Sanity Group") Acquisition: Subsequent to quarter-end, Organigram completed its acquisition of one of Germany's cannabis leaders, Sanity Group. Sanity Group is expected to generate approximately €25 million in average quarterly revenue over the next calendar year, and provide a scalable platform to accelerate Organigram's growth across key European markets.

•Australia Branded Sales: Launched 10 vape and gummy SKUs in Australia under the BOXHOT and Edison brands, with products expected to be available to over 4,000 pharmacies.

•Record Yield and Potency: Achieved a record quarterly harvest of over 32,000 kg (+56% year-over-year) and the highest average THC potency across the Company's flagship Moncton facility compared to any prior quarter due to continued enhancements to cultivation practices.

•Plant Science: Advancing Organigram's recent achievements in early-stage genetic marker identification, the Company launched two powdery mildew resistant cultivars and continues progress toward the identification of other genetic traits including, but not limited to aroma, color, terpene expression, and disease resistance.

“Q2 reflected our underperformance in vapes and temporary challenges in infused pre-roll production, compounded by slower industry growth,” said James Yamanaka, CEO of Organigram. “We acted quickly to address these issues, and the operational changes and product enhancements we have implemented are already beginning to stabilize performance. Combined with continued improvements in yields and flower potency, and the contribution from Sanity Group beginning in Q3, we believe the business is positioned for stronger execution and improved performance in the second half of fiscal 2026.”

SECOND QUARTER FISCAL 2026 FINANCIAL OVERVIEW

•Net revenue:

◦Net Revenue decreased 9% to $59.8 million, from $65.6 million in the second quarter ended March 31, 2025 ("Q2 Fiscal 2025"), primarily driven by lower vape and infused pre-roll sales.

•Adjusted gross margin2:

1 Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of March, 2026.

2 Adjusted gross margin, adjusted gross margin %, and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to "Non-IFRS Financial Measures" in this press release for more information.

1

◦Adjusted gross margin was $18.4 million, or 31% of net revenue, compared to $21.9 million, or 33%, in Q2 Fiscal 2025. The year-over-year decrease in adjusted gross margin was primarily driven by changes in product mix, including a lower proportion of higher-margin product categories in the current period, and higher product returns.

•Selling, General & Administrative ("SG&A") Expenses:

◦SG&A increased to $23.6 million from $22.5 million in Q2 Fiscal 2025. The increase was primarily driven by higher investments in advertising, promotions, and trade marketing initiatives to support new product launches in the current period, and a credit loss due to a wholesale customer insolvency.

◦As a proportion of net revenue, SG&A increased to 39%, compared to 34% in Q2 Fiscal 2025.

•Net Income or loss:

◦Net loss was $0.9 million compared to net income of $42.5 million in Q2 Fiscal 2025. The decrease in net income in the current period was primarily attributable to lower fair value gains on derivative liabilities and preferred shares, as well as lower net revenue and gross margins compared to the prior year period. In addition, the current period results were negatively impacted by a $5.8 million impairment loss related to the Company's hemp-derived products business in the U.S.

•Adjusted EBITDA3:

◦Adjusted EBITDA was $0.9 million compared to $4.9 million in adjusted EBITDA in Q2 Fiscal 2025. The decrease in Adjusted EBITDA compared to the comparative period is primarily due to lower recreational revenue while operating expenses remained flat as a proportion of net revenue, as well as the impact of higher returns provisions.

•Net Cash used in Operating Activities:

◦Cash used in operating activities was $6.8 million, compared to $16.6 million in Q2 Fiscal 2025. The improvement was primarily attributable to lower investment in working capital, partially offset by lower adjusted EBITDA3.

•Free Cash Flow ("FCF")3:

◦FCF was an outflow of $7.0 million compared to $23.1 million in Q2 Fiscal 2025. The improvement was primarily attributable to lower investment in working capital and lower capital expenditures.

“The financial impact of the competitive and operational challenges encountered earlier in Fiscal 2026 is believed to have been largely realized in the first half of the year, and we are now beginning to see performance stabilize,” said Greg Guyatt, Chief Financial Officer of Organigram. “While margins and profitability were pressured during the quarter, the underlying cost structure of the business continues to improve, supported by higher yields, operational efficiencies, and prior investments in automation. We expect to resume our trajectory of margin expansion and profitability improvement through the second half of the year, supported by expected growth in net revenue and international sales, alongside positive contributions from the consolidation of Sanity Group.”

INTERNATIONAL SALES

3 Adjusted gross margin, adjusted gross margin %, Free Cash Flow, and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to "Non-IFRS Financial Measures" in this press release for more information.

2

•In Q2 Fiscal 2026, Organigram generated $6.1 million in international sales, consistent with the prior year period. Performance reflected an elevated proportion of product that did not meet international specifications during the quarter. Sequentially, international sales increased from $5.0 million in Q1 Fiscal 2026, driven by improving on-spec volumes. The Company expects continued progress in international on-spec volumes through the second half of Fiscal 2026.

•In April 2026 Organigram provided all additional documentation requested by the regulator to date to support the closure of all major findings identified in its EU-GMP certification audit. The Company expects an update on certification in the coming months.

BALANCE SHEET & LIQUIDITY

•As of March 31, 2026, the Company had total cash (including restricted cash and short-term investments) of $54.8 million.

•Subsequent to quarter end, the Company deployed the majority of its total cash position in consideration of the Sanity Group acquisition and secured $60 million in debt financing from ATB Financial of which $20 million was allocated to the Sanity Group acquisition.

FISCAL 2026 GUIDANCE

•The Company originally issued its Fiscal 2026 guidance in Q4 Fiscal 2025, prior to the acquisition of Sanity Group, which closed in April 2026. At that time, the Company contemplated net revenue exceeding $300 million, higher Adjusted Gross Margin4 and Adjusted EBITDA4 relative to Fiscal 2025, positive Free Cash Flow4, and capital expenditures of less than $10 million.

•Following the acquisition of Sanity Group, which closed in April 2026, the Company is updating its Fiscal 2026 guidance. Prior to the acquisition, shipments to Sanity Group were recognized as revenue upon shipment to Sanity Group; post-acquisition, shipments to Sanity Group are recognized as revenue upon ultimate sale by Sanity Group to third parties. The Company is now projecting net revenue to exceed $350 million in Fiscal 2026, with Adjusted EBITDA4 and Adjusted Gross Margin4 exceeding Fiscal 2025 performance, Free Cash Flow4 approximately break even, and capital expenditures of less than $10 million.

4 Adjusted gross margin, adjusted gross margin %, Free Cash Flow, and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to "Non-IFRS Financial Measures" in this press release for more information.

3

Select Key Financial Metrics  (in $000s unless otherwise indicated)			Q2-2026			Q2-2025			% Change
Gross revenue			93,250			102,763			(9)		%
Excise taxes			(33,456)			(37,163)			(10)		%
Net revenue			59,794			65,600			(9)		%
Cost of sales			44,800			45,813			(2)		%
Gross margin before fair value changes to biological assets & inventories sold			14,994			19,787			(24)		%
Realized fair value on inventories sold and other inventory charges			(21,834)			(14,192)			54		%
Unrealized gain on changes in fair value of biological assets			23,247			12,823			81		%
Gross margin			16,407			18,418			(11)		%
Adjusted gross margin(1)			18,441			21,921			(16)		%
Adjusted gross margin %(1)			31		%	33		%	(2)		%
Selling (including marketing), general & administrative expenses			23,609			22,490			5		%
Net (loss) income			(921)			42,456			nm
Adjusted EBITDA(1)			870			4,908			(82)		%
Net cash used in operating activities before working capital changes			(6,211)			(1,607)			286		%
Net cash used in operating activities after working capital changes			(6,760)			(16,585)			(59)		%

Note (1) Adjusted gross margin, adjusted gross margin % and adjusted EBITDA are non-International Financial Reporting Standards ("IFRS") financial measures not defined by and do not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to “Non-IFRS Financial Measures” in this press release for more information.

Select Balance Sheet Metrics (in $000s)			MARCH 31, 2026			SEPTEMBER 30, 2025			% Change
Cash & short-term investments (including restricted cash)			54,754			84,420			(35)		%
Biological assets & inventories			135,158			123,954			9		%
Other current assets			60,174			76,523			(21)		%
Accounts payable & accrued liabilities			73,139			89,247			(18)		%
Working capital			161,341			158,738			2		%
Property, plant & equipment			120,838			122,977			(2)		%
Total assets			521,312			562,211			(7)		%
Total liabilities			149,500			213,081			(30)		%
Shareholders’ equity			371,812			349,130			6		%

RECONCILIATION

The following table reconciles the Company's adjusted EBITDA to net income (loss).

4

Adjusted EBITDA Reconciliation  (in $000s unless otherwise indicated)			Q2-2026			Q2-2025
Net (loss) income as reported			$	(921)		$	42,456
Add/(deduct):
Investment income, net of financing costs			(312)			(179)
Income tax expense (recovery)			—			(106)
Depreciation and amortization			5,033			4,839
Impairment of property, plant and equipment, intangible assets and goodwill			5,800			—
ERP implementation costs			120			628
Acquisition and transaction costs			4,356			974
Inventory and biological assets fair value and NRV adjustments			2,034			1,917
Incremental fair value component on inventories sold from acquisitions			—			1,586
Share-based compensation			728			938
Other (income) expenses(1)			(18,716)			(50,728)
Provision for non-recurring credit losses			821			—
Research and development expenditures, net of depreciation			1,927			2,583
Adjusted EBITDA			$	870		$	4,908

Note (1):    Other (income) expenses includes share of loss from investments in associates, (gain) loss on disposal of property, plant and equipment, change in fair value of derivative liabilities, preferred shares, contingent consideration and other financial assets, and certain other non-operating (income) expenses.

The following table reconciles the Company's adjusted gross margin to gross margin before fair value adjustments:

Adjusted Gross Margin Reconciliation (in $000s unless otherwise indicated)			Q2-2026			Q2-2025
Net revenue			$	59,794		$	65,600
Cost of sales before adjustments			41,353			43,679
Adjusted gross margin			18,441			21,921
Adjusted gross margin %			31		%	33		%
Less:
Provisions and impairment of inventories and biological assets			3,420			548
Provisions to net realizable value			27			—
Gross margin before fair value adjustments			14,994			19,787
Gross margin % (before fair value adjustments)			25		%	30		%
Add:
Realized fair value on inventories sold and other inventory charges			(21,834)			(14,192)
Unrealized gain on changes in fair value of biological assets			23,247			12,823
Gross margin			16,407			18,418
Gross margin %			27		%	28		%

The following table reconciles the Company's Free Cash Flow to net cash and restricted cash provided by (used in) operating activities:

5

Free Cash Flow Reconciliation (in $000s unless otherwise indicated)			Q2-2026			Q2-2025
Net cash and restricted cash provided by (used in) operating activities			$	(6,760)		$	(16,585)
Less:
Purchase of property, plant and equipment			(223)			(6,508)
Free Cash Flow			(6,983)			(23,093)

Second Quarter Fiscal 2026 Conference Call

The Company will host a conference call to discuss its results with details as follows:

Date:    May 12, 2026

Time:    8:00 am Eastern Time

To register for the conference call, please use this link:

https://events.q4inc.com/analyst/574618022?pwd=FVnom6fM

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast:

https://events.q4inc.com/attendee/574618022

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.

Non-IFRS Financial Measures

This news release refers to certain financial performance measures (including adjusted gross margin, adjusted gross margin %, adjusted EBITDA and free cash flow) that are not defined by and do not have a standardized meaning under IFRS as issued by the International Accounting Standards Board. Non-IFRS financial measures are used by management to assess the financial and operational performance of the Company. The Company believes that these non-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company’s operating results, underlying performance and prospects in a similar manner to the Company’s management. As there are no standardized methods of calculating these non-IFRS measures, the Company’s approaches may differ from those used by others, and accordingly, the use of these measures may not be directly comparable. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Adjusted EBITDA is a non-IFRS measure that the Company defines as net income (loss) excluding: financing costs, net of investment income; income tax expense (recovery); depreciation, amortization, impairment, normalization of depreciation add-back due to changes in depreciable assets resulting from impairment charges, (gain) loss on disposal of property, plant and equipment (per the consolidated statement of cash flows); share-based compensation (per the consolidated statement of cash flows); share of loss (gain) from investments in associates including impairment loss; change in fair value of contingent consideration; change in fair value of derivative liabilities, other financial assets and preferred shares; expenditures incurred in connection with research and development activities (net of depreciation); unrealized gain on changes in fair value of biological assets; realized fair value on inventories sold and other inventory charges; provisions and net realizable value adjustments

6

related to inventory and biological assets; government subsidies, insurance recoveries and other non-operating expenses (income); legal provisions (recoveries); ERP implementation costs; transaction costs; share issuance costs; and provision for Canndoc expected credit losses. Adjusted EBITDA is intended to provide a proxy for the Company’s operating cash flow and derives expectations of future financial performance for the Company, and excludes adjustments that are not reflective of current operating results.

Adjusted gross margin is a non-IFRS measure that the Company defines as net revenue less cost of sales, before the effects of (i) unrealized gain on changes in fair value of biological assets; (ii) realized fair value on inventories sold and other inventory charges; (iii) realized fair value on inventories sold from acquisitions; (iv) provisions and impairment of inventories and biological assets; and (v) provisions to net realizable value. Adjusted gross margin % is calculated by dividing adjusted gross margin by net revenue. Management believes that these measures provide useful information to assess the profitability of our operations as they represent the normalized gross margin generated from operations and exclude the effects of non-cash fair value adjustments on inventories and biological assets, which are required by IFRS.

Free cash flow provided by (used in) operating activities is calculated as net cash provided by or used in operating activities less the purchase of property, plant and equipment. Free cash flow is a useful indicator of the Company's capacity to fund operations from internally generated cash flows, without the need for additional borrowings or use of existing cash reserves under normal operating conditions.

The most directly comparable measure to adjusted EBITDA, calculated in accordance with IFRS is net income (loss) and see "Reconciliation" section of this press release for a reconciliation to such measure. The most directly comparable measure to adjusted gross margin calculated in accordance with IFRS is gross margin before fair value adjustment and see "Reconciliation" section of this press release for a reconciliation to such measure. The most directly comparable measure to Free Cash Flow is net cash and restricted cash provided by (used in) operating activities, and see "Reconciliation" section of this press release for a reconciliation to such measure.

About Organigram Global Inc.

Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly-owned subsidiaries include Organigram Inc., a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Limited, Organigram Global participates in the U.S. and Canadian cannabinoid beverages markets.

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, Collective Project, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Québec, with a dedicated manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information

7

This news release contains forward-looking information. Forward-looking information, in general, can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “could”, “would”, “might”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “continue”, “budget”, “schedule” or “forecast” or similar expressions suggesting future outcomes or events. They include, but are not limited to, statements with respect to expectations, projections or other characterizations of future events or circumstances, and the Company’s objectives, goals, strategies, beliefs, intentions, plans, estimates, forecasts, projections and outlook, including statements relating to the Company’s future performance, the Company’s positioning to capture additional market share and sales including international sales and the expected continued progress in international on-spec volumes, expectations for consumer demand, expected improvement to gross margins before fair value changes to biological assets and inventories, expectations regarding adjusted gross margins, adjusted EBITDA, Free Cash Flow and net revenue in Fiscal 2026 and beyond, expectations regarding cultivation capacity, the Company’s plans and objectives including around the availability and sources of any future financing, availability of cost efficiency opportunities, the ability of the Company to fulfill demand for its revitalized product portfolio with increased staffing, expectations relating to greater capacity to meet demand due to increased capacity at the Company’s facilities, expectations around lower product cultivation costs, the ability to achieve economies of scale and ramp up cultivation, expectations pertaining to the increase of automation and reduction in reliance on manual labour, expectations around the launch of higher margin dried flower strains, expectations around market and consumer demand and other patterns related to existing, new and planned product forms; expectations regarding the Company's integration of Sanity Group, including the expected revenue to be generated by Sanity Group over the next calendar year; expectations around FASTTM nanoemulsion technology; expectations regarding EU-GMP certification; timing for launch of new product forms, ability of those new product forms to capture sales and market share, estimates around incremental sales and more generally estimates or predictions of actions of customers, suppliers, partners, distributors, competitors or regulatory authorities; statements regarding the future of the Canadian and international cannabis markets and, statements regarding the Company’s future economic performance. These statements are not historical facts but instead represent management beliefs regarding future events, many of which, by their nature are inherently uncertain and beyond management control. Forward-looking information has been based on the Company’s current expectations about future events.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. These risks, uncertainties and factors include: general economic factors; geopolitical risks; international trade disputes sparked by tariffs and retaliatory tariffs or other non-tariff measures; changes to government laws, regulations or policies, including customs, tariffs, trade or environmental law, regulations or policies, or the enforcement thereof; receipt of regulatory approvals or consents and any conditions imposed upon same and the timing thereof; the Company's ability to meet regulatory criteria which may be subject to change; change in regulation including restrictions on sale of new product forms; change in stock exchange listing practices; the Company's ability to manage costs, timing and conditions to receiving any required testing results and certifications; results of final testing of new products; changes in governmental plans including those related to methods of distribution; timing and nature of sales and product returns; customer buying patterns and consumer preferences not being as predicted given this is a new and emerging market; material weaknesses identified in the Company’s internal controls over financial reporting; the completion of regulatory processes and registrations including for new products and forms; market demand and acceptance of new products and forms; unforeseen construction or delivery delays including of equipment and commissioning; increases to expected costs; competitive and industry conditions; change in customer buying patterns; and changes in crop yields. These and other risk factors are disclosed in the Company's documents filed from time to time under the Company’s issuer profile on the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval+ (“SEDAR”) at www.sedarplus.ca and reports and other information filed with or furnished to the United States Securities and Exchange

8

Commission (“SEC”) from time to time on the SEC’s Electronic Document Gathering and Retrieval System (“EDGAR”) at www.sec.gov, including the Company’s most recent management discussion and analysis ("MD&A") and annual information form. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release.

Certain forward-looking information included herein may also constitute a "financial outlook" within the meaning of applicable securities legislation. Financial outlook involves statements about the Company’s prospective financial performance and financial position that are based on and subject to the assumptions about future economic conditions and courses of action described above as well as management's expectations regarding a strong innovation pipeline, increasing international sales, high cannabis quality and higher potency, commercialization of FAST nano emulsion technology in ingestible formats, and receipt of the EU-GMP certification. Such assumptions are based on management's assessment of the relevant information currently available and any financial outlook included herein is provided for the purpose of helping readers understand management's current expectations and plans for the future as of the date hereof. The actual results of the Company’s operations may vary from the amounts set forth in any financial outlook and such variances may be material. Readers are cautioned that reliance on any financial outlook may not be appropriate for other purposes or in other circumstances and that the risk factors described above and other factors may cause actual results to differ materially from any financial outlook.

The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward looking information is subject to risks and uncertainties that are addressed in the “Risk Factors” section of the MD&A dated May 12, 2026 and there can be no assurance whatsoever that these events will occur.

Third-Party Information

This news release contains information concerning our industry and the markets in which we operate, including our market position and market share, which is based on information from independent third-party sources. Although we believe these sources to be generally reliable, market and industry data is inherently imprecise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey or data collection process. We have not independently verified any third-party information contained herein.

For Investor Relations enquiries, please contact:

Max Schwartz, Director of Investor Relations

investors@organigram.ca

For Media enquiries, please contact:

Megan McCrae, Senior Vice President, Global Brands and Corporate Affairs

megan.mccrae@organigram.ca

9

FAQ

How did Organigram (OGI) perform financially in Q2 Fiscal 2026?

Organigram generated $59,794 in net revenue in Q2 Fiscal 2026, down 9% year over year, and reported a net loss of $921. Adjusted EBITDA fell to $870 as recreational cannabis sales declined and margins softened due to product mix and higher returns provisions.

What were Organigram’s six-month results to March 31, 2026?

For the six months ended March 31, 2026, Organigram posted net revenue of $123,332, up 14% from the prior year period. Adjusted gross margin rose to $42,296 or 34%, and net income was $19,048, reflecting higher recreational and international sales and gains on biological asset fair values.

What is significant about Organigram’s acquisition of Sanity Group?

In April 2026, Organigram closed the acquisition of Sanity Group for upfront consideration of €107.3 million, including €78.0 million in cash and €29.3 million in shares. The deal expands Organigram’s presence in Germany’s medical cannabis market and supports broader European and international revenue growth plans.

How has Organigram updated its Fiscal 2026 guidance after recent transactions?

Following the Sanity Group acquisition, Organigram now projects Fiscal 2026 net revenue to exceed $350 million, up from prior guidance above $300 million. Management also expects adjusted EBITDA and adjusted gross margin to exceed Fiscal 2025 and free cash flow to be approximately break even, with capital expenditures below $10 million.

What regulatory risks does Organigram face in the U.S. hemp-derived THC market?

The Continuing Appropriations and Extensions Act of 2026 redefines hemp to effectively eliminate many hemp-derived THC products starting November 12, 2026. Organigram’s U.S. offerings and related investments would be directly impacted, and the company may need to sell, wind down or restructure its hemp THC activities by November 2026 if the law is unchanged.

What internal control issues has Organigram disclosed?

Management identified a material weakness in internal control over financial reporting related to management review controls for complex spreadsheets used in biological asset and inventory valuation. Although certain IT system issues have been remediated, these spreadsheet-related controls are still being strengthened and tested during Fiscal 2026.

How strong is Organigram’s liquidity and balance sheet as of March 31, 2026?

At March 31, 2026, Organigram reported cash, restricted cash and short-term investments of $54,754, working capital of $161,341, and total shareholders’ equity of $371,812. Subsequent to quarter-end, it added a $60 million senior secured credit facility to support liquidity and fund the Sanity Group acquisition.

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 614.5 KB
• EX-99.2 EX-99.2 597.3 KB
• EX-99.3 EX-99.3 16.1 KB
• EX-99.4 EX-99.4 15.7 KB
• EX-99.5 EX-99.5 157.8 KB